Mitochondrial nucleoid in cardiac homeostasis: bidirectional signaling of mitochondria and nucleus in cardiac diseases

Yuliang Feng1 · Wei Huang2 · Christian Paul2 · Xingguo Liu3,4,5 · Sakthivel Sadayappan6 · Yigang Wang2 · Siim Pauklin1

Received: 10 June 2021 / Accepted: 20 July 2021 / Published online: 14 August 2021 © The Author(s) 2021

Abstract
Metabolic function and energy production in eukaryotic cells are regulated by mitochondria, which have been recognized as the intracellular ‘powerhouses’ of eukaryotic cells for their regulation of cellular homeostasis. Mitochondrial function is important not only in normal developmental and physiological processes, but also in a variety of human pathologies, including cardiac diseases. An emerging topic in the field of cardiovascular medicine is the implication of mitochondrial nucleoid for metabolic reprogramming. This review describes the linear/3D architecture of the mitochondrial nucleoid (e.g., highly organized protein-DNA structure of nucleoid) and how it is regulated by a variety of factors, such as noncoding RNA and its associated R-loop, for metabolic reprogramming in cardiac diseases. In addition, we highlight many of the presently unsolved questions regarding cardiac metabolism in terms of bidirectional signaling of mitochondrial nucleoid and 3D chromatin structure in the nucleus. In particular, we explore novel techniques to dissect the 3D structure of mitochondrial nucleoid and propose new insights into the mitochondrial retrograde signaling, and how it regulates the nuclear (3D) chromatin structures in mitochondrial diseases.

Keywords Mitochondrial nucleoid · 3D genome Organization · Metabolic reprogramming · Cardiovascular diseases

Abbreviations
CARs Chromatin-associated RNAs
circRNAs Circular ncRNAs
CMD Coronary microvascular dysfunction
CTCF CCCTC-binding factor
DCM Dilated cardiomyopathy
csA Cyclosporin A
ETC Electron transport chain
GQs G-quadruplex sequences
HIF-1α Hypoxia inducible factor 1α
DAMPs Damage-associated molecular patterns
DdCBEs DddA-derived cytosine base editors

Yuliang Feng and Wei Huang are Co-first authors

Yuliang Feng
wanyy@ucmail.uc.edu

Siim Pauklin
siim.pauklin@ndorms.ox.ac.uk

1 Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Old Road, University of Oxford, Oxford OX3 7LD, UK
2 Department of Pathology and Laboratory Medicine, Regenerative Medicine Research, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0529, USA
3 Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), CAS Key Laboratory of Regenerative Biology, Joint School of Life Sciences, Hefei Institute of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China
4 Guangzhou Regenerative Medicine and Health Guangdong Laboratory, CAS Key Laboratory of Regenerative Biology, Joint School of Life Sciences, Hefei Institute of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Guangzhou Medical University, Guangzhou 510530, China
5 Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Institute for Stem Cell and Regeneration, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China
6 Heart, Lung and Vascular Institute, Division of Cardiovascular Health and Disease, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH 45267, USA

Springer
**Introduction**

Cells can survive in a diversity of environments and reprogram their energy metabolism to adapt to nutritional changes in the microenvironment. This process is commonly referred to as ‘metabolic reprogramming’, and it is an emerging hallmark of the cell-fate decision process [72]. For cellular metabolism and energy production, mitochondria have been recognized as the key hub where metabolic pathways converge and integrate. In particular, this review will focus on mitochondrial metabolism as the primary energy source for the heart. This review will discuss the essential roles of mitochondria in cardiac homeostasis, including cardiac development and differentiation. In addition, mitochondrial dysfunction is a characteristic feature of various cardiac diseases, such as heart failure, owing to an insufficient supply of ATP. It has been well established that transcriptional dysregulation of the mitochondrial genome is central to mitochondrial dysfunction, but the underlying mechanisms are largely unexplored. We further explore the architecture of the mitochondrial genome, its potential regulators, e.g., mitochondrial ncRNA translocated from the nucleus, and how they orchestrate mitochondrial transcription in cardiac metabolic reprogramming. Lastly, we revisit mitochondrial retrograde signaling, its potential impact on nuclear chromatin structures, e.g., 3D chromatin topology, and its implications for mitochondrial diseases, which typically first present with cardiomyopathy (Fig. 1). Collectively, we believe that this review will provide a fresh conceptual look that will allow dissection of the molecular mechanisms of metabolic reprogramming in cardiac diseases.

**Mitochondrial structure and function in cardiac homeostasis**

**Mitochondria in heart development**

The mitochondrion is a lipid bilayer membrane organelle. It is highly enriched in adult cardiomyocytes which occupy a large portion (approximately 20–30%) of the cytoplasmic space and produce 90% of ATP [193]. Mitochondria contain an outer membrane and inner membrane, two aqueous sub-compartments known as the intermembrane space (IMS) between the two membranes, and the matrix within the inner membrane. The outer membrane is a double phospholipid membrane which is similar to the eukaryotic cell membrane. The outer membrane not only separates the mitochondrion from the cytoplasm, but also contains multiple receptors to mediate communication between mitochondria and other organelles. In addition, some special regions of the outer membrane have been shown to interact with other organelles or other mitochondria, including (i) mitochondria-associated endoplasmic reticulum membranes (MAMs) and (ii) intermitochondrial junctions (IMJs). The intermembrane space contains cytochrome c, which is involved in electron transport and apoptosis regulation. The inner membrane is the site of oxidative phosphorylation (OXPHOS) complexes (complexes I–V) which are involved in electron transport and ATP synthesis. The inner membrane also folds and creates a layered structure named cristae that protrude into the matrix to increases the surface area for energy production. The matrix is enriched in the enzymes and chemicals of the Krebs tricarboxylic acid (TCA) and fatty acid cycle, mitochondrial DNA (mtDNA), ribosomes, enzymes, and ions.

During heart development, the mitochondrial system is dynamically regulated to support ATP synthesis, energy transduction, and cell signaling events (Fig. 2). The increase in mitochondrial mass in the growing heart is accompanied by structural differentiation into interfibrillar (IFM) and subsarcolemmal mitochondria (SSM) [43]. These two mitochondrial subpopulations exhibit distinct location, morphology, and functional characteristics. Elongated IFMs are tightly packed into the space between sarcomere Z-lines and lined with sarcoplasmic reticulum, providing ATP for contraction and having higher calcium (Ca^{2+}) accumulation. In contrast, the SSMs are located beneath the sarcolemma and provide ATP for active transport of electrolytes and metabolites across the sarcolemma [94, 154]. It has also been reported that the stress response of these two mitochondrial subpopulations are different under pathological conditions, such as cardiac volume [214] and pressure overload [194], hypoxia...
Metabolic changes also occur during the developing heart. Immature mitochondria can be observed in cardiomyocytes in mice from embryonic day 8.5 (E8.5) to E10.5, and some very immature mitochondria can be observed in cardiomyocytes, as characterized by low cristae density, absence of SSM/IFM specialization, and lactose metabolism. Although OXPHOS complexes can be detected in the inner membrane of mitochondria, cardiomyocytes at these stages primarily acquire ATP through anaerobic glycolysis [180]. Intriguingly, embryonic development will be terminated at E8.5 mouse models lacking essential mitochondrial components [28, 31, 105, 130] and all heart structure [28], suggesting that mitochondria also play a pivotal role in heart development. The number of cristae in cardiomyocytes is increased in mice from E11.5 to E13.5, and many tubular cristae are formed that are connected with the periphery. By E13.5, the functionally matured mitochondria are observed, and cardiomyocytes at this stage acquire ATP through both anaerobic glycolysis and OXPHOS [37, 146]. Noticeably, the mitochondrial permeability transition pore (mPTP) is closed at E13.5, which has been reported to drive mitochondrial elongation, higher mitochondrial membrane potential and cardiomyocyte differentiation in mouse hearts [95]. From E13.5 to prenatal stages, the ATP production pathway shifts from anaerobic glycolysis to aerobic metabolism [69, 146]. At the end of gestation, OXPHOS provides >50% of ATP in prenatal hearts. Shortly after birth and during the first week of postnatal stages, mitochondrial biogenesis is increased, and the mitochondrial mass of cardiomyocytes is doubled [43, 75]. In addition, the energy metabolism shifts from glucose- and lactate-consuming respiration to the more energy producing β-oxidation of fatty acids.

Fig. 1 Overview of regulation of mitochondrial nucleoid and its crosstalk with nucleus. Mito-nucleus crosstalk is essential for cell-fate plasticity (differentiation and reprogramming), while its miscommunication is involved in the pathogenesis of heart diseases.
One reason for the change of energy metabolism from glycolysis to OXPHOS in developing heart may be the development of hypoxia inducible factor 1α (HIF-1α) signaling. In the embryonic and fetal (prenatal) heart, HIF-1α is activated in the presence of a hypoxic environment, whereas HIF-1α signaling is decreased in cardiomyocytes after birth [146, 147, 168]. These studies emphasize the importance of mitochondrial homeostasis as essential for embryonic heart development.

Mitochondria in cardiac differentiation and maturation in pluripotent stem cells

Although mitochondria play an important role in heart development, little is known about their function at the cardiac precursor stage as a result of technical limitations. With the development of efficient cardiac differentiation protocols, the process of cardiac differentiation from pluripotent stem cells (PSCs) is known to recapitulate early cardiac development, thereby providing a potential source for studying otherwise inaccessible cells or tissues. To maintain pluripotency, PSCs mainly depend on glucose and glutamine metabolism. When PSCs exit from pluripotency to the mesoderm, metabolism switches away from glycolysis to OXPHOS which is modulated by several key signaling pathways, including MYC/ MYCN transcription inhibition, insulin inhibition, GSK3 inhibition, and Yap inhibition. Upon differentiation, PSCs also display increased numbers and maturation of mitochondria [88]. Studies in PSC cardiac differentiation further suggest that mitochondrial maturation, mitochondrial dynamics, and metabolic shift are prerequisites for the differentiation of stem cells into a functional cardiac phenotype (Fig. 2). In mouse and human PSC-derived cardiomyocytes, the level of mitochondrial OXPHOS and cristae maturation is significantly increased compared to those in PSC, whereas glycolysis is decreased [37]. Inhibition of OXHOS during cardiac differentiation prevents mitochondrial organization, causing poor cardiomyocyte differentiation, as characterized by deficient sarcomerogenesis and contractile malfunction [37]. Consistent with mouse developing heart, the fragmented mitochondrial network in PSCs progressively fuses and elongates during differentiation, which further confirms the
essential role of mitochondrial fusion in proper cardiomyocyte differentiation [112]. mPTP inhibition by Cyclosporin A (CsA) facilitates the differentiation of functional cardiomyocytes from mouse and human PSCs [35]. Moreover, the differentiated cardiomyocytes display unique metabolic features in contrast to non-cardiomyocytes. PSC-derived non-cardiomyocytes proliferate and mainly rely on glucose and glutamine metabolism; however, differentiated cardiomyocytes rely on lactate oxidation [211, 212]. Understanding the metabolic cues in heart development not only facilitates cardiac differentiation, but also enables the development of nongenetic methods to purify PSC-derived cardiomyocytes for clinical applications [88].

**Mitochondrial regulation of cardiac diseases**

Accumulating evidence has demonstrated the central role of mitochondria in the preservation of cardiac homeostasis. Major theories of mitochondrial dysregulation, including mitochondrial DNA (mtDNA) mutation/damage, impaired OXPHOS, defects in mitochondrial translation, imbalanced mitochondrial dynamics, dysregulated lipid metabolism, and mitochondrial Ca$^{2+}$ overload, are all associated with progressive decline in myocardial structure and function (Fig. 3). The mtDNA has a very high rate of mutation [162, 185], but only limited repair capacity [245]. Therefore, mtDNA mutation and inadequate mtDNA level compromise the integrity of the mitochondrial genome, resulting in defects in electron transport chain (ETC) complexes and ATP supply. Various mtDNA mutations have been detected in heart tissues. Genetic defects in ETC structure subunits of the OXPHOS system (complex I, II or III) [5, 7, 29, 161] and proteins associated with proper assembly of respiratory chain complexes [30], such as mutation in COX10 and COX15 or the assembly factors of complex IV [8], have been described in different types of cardiomyopathy. Recently, pathogenic mutations in components of the mitochondrial translation machinery have also been linked to various progressive human diseases, including neurological disorders, heart/muscle diseases, and endocrine problems [127]. During translation of mitochondrial mRNAs, various translation factors interact with the mitochondrial ribosome to synthesize the polypeptides.

Fig. 3  Mitochondrial regulation of cardiac diseases. Schematic view of major mitochondrial dysregulation implicated in progressive decline of myocardial structure and function, including mitochondrial DNA (mtDNA) mutation/damage (red color) and defects in mitochondrial translation (purple color) (A), impaired assembly of ETC and OXPHOS (blue color) (B), imbalanced mitochondrial dynamics (C), dysregulated lipid metabolism (D), and mitochondrial Ca$^{2+}$ overload (E). LS Leigh syndrome, LHON Leber hereditary optic neuropathy, MELAS mitochondrial encephalomyopathy, lactacidosis and stroke-like episodes, NARP neurogenic muscle weakness, ataxia and retinitis pigmentosa, MILS maternally inherited Leigh syndrome.
Mitochondrial RNA contains two mitochondrial ribosomal RNAs (12S mt-rRNA and 16S mt-rRNA) and 22 mt-tRNAs encoded by mtDNA. Mutation of mt-rRNAs [52, 145, 192], mt-tRNAs [4, 74, 76], mitochondrial ribosomal proteins (MRPL3 and MRPL44), and the translation elongation factor (TSFM) [1, 48, 54, 65] have all been documented in various cardiomyopathies, together with decreased synthesis of mitochondrial polypeptides and impaired energy production. As highly dynamic organelles, homeostasis of mitochondria is tightly controlled by a quality control system consisting of fission, fusion, and degradation of mitochondria, collectively referred to as mitochondrial dynamics. Fusion involves content exchange, allowing complementation of mitochondrial solutes, proteins and DNA. Fission allows segregation of damaged mitochondria eliminated by selective degradation (mitophagy). Mitochondrial dynamics is essential for mitochondrial shape, size, distribution, quality control (mitophagy), and transport of mitochondria within the cell. For example, when cells are challenged by stress, mitochondrial dynamics spring into action to trigger compensatory and adaptive cellular response [49, 176].

Pathogenic mutations in the core machinery and defects of mitochondrial dynamics-related proteins have been documented in various cardiac diseases. Recently, mitochondrial lipid metabolism was found to play an important role in the regulation of mitochondrial dynamics [70]. Although most lipids are synthesized in the endoplasmic reticulum (ER), the mitochondrial membrane also contributes to phospholipid synthesis, including cardiolipin (CL), phosphatidic acid, and phosphatidylethanolamine (PE) [157]. Mitochondrial lipid metabolism has been associated with cardiomyopathy in Barth syndrome (BTHS), an x-linked autosomal recessive disease [103]. The underlying cause of BTHS is the mutation of CL transacylase tafazzin (TAZ), which results in the impaired synthesis of CL and compromises mitochondrial homeostasis. CL is a highly abundant lipid in heart tissues and is important in maintaining mitochondrial homeostasis, ranging from mitochondrial protein transport, mitochondrial dynamics, mitochondrial cristae formation, and respiratory chain to cytochrome c-related apoptosis [51]. CL directly interacts with optic atrophy 1 (Opa1), a core component of mitochondrial fusion machinery [70], and it is also associated with the processing of Opa1 [172]. Impaired Opa1 processing has been reported to cause dilated cardiomyopathy and heart failure [221], indicating an intriguing involvement of CL-regulated Opa1 processing. Interestingly, mtDNA-protein complexes were found to be co-fractionated with mitochondrial lipid components [71]. Further research has shown that mtDNA stability and segregation are associated with mitochondrial lipid metabolism [148]. Recent studies of mitochondrial Ca\(^{2+}\) overload have revealed a critical role in the pathophysiology of heart failure [240]. Specifically, excessive Ca\(^{2+}\) in mitochondria will increase the generation of ROS and mPTP opening, thereby causing mitochondrial dysfunction and cell death [163]. No direct evidence has suggested that mtDNA polymorphisms/mutations are involved in dysregulated mitochondrial Ca\(^{2+}\) in heart diseases. Nevertheless, it has been documented that mtDNA polymorphisms alter mitochondrial calcium levels in forebrain cells of mutant mtDNA polymerase (Polg) transgenic mice [114]. These studies put the mitochondrial genome squarely in the center of the cardiac homeostatic network which is responsible for coordinating the involvement of mitochondria in cellular homeostasis.

**Higher organization of the mitochondrial genome**

**The mitochondrial genome forms highly organized protein–DNA structures in the nucleoid**

Mitochondria are endosymbiotic organelles containing their own genome, mtDNA. The mtDNA, as an ‘extranuclear’ genetic molecule, is unique and different from nuclear DNA (nDNA), the regulation of which is independent from nDNA. The mtDNA is generally packaged into nucleoids, the heritable units of mtDNA. The organization of mtDNA is compact without intronic structures in protein-coding genes and often contains overlapping reading frames between neighboring genes, thereby leading to higher gene density in mtDNA than that in nDNA [243]. The size of mtDNA is small, the mRNA transcribed from mtDNA can represent a surprisingly large proportion of total cellular mRNA, nearly 30% in the heart [159]. Mammalian mtDNA is a compact circular DNA molecule of 16,569 base pairs with a contour length of 5 µm that possesses coding regions (> 90%, around 93% in humans and mice) and noncoding regions. The coding regions encode 11 tRNAs (translated to critical proteins of the OXPHOS), 2 ribosomal RNAs (rRNAs, 12S and 16S), and 22 transfer RNAs (tRNAs). The noncoding regions include D-loop and the light-strand origin of replication (OriL) that harbors regulatory regions for mtDNA transcription and replication.

Unlike nDNA, mtDNA lacks histones and is packaged into the nucleoid, as noted above, inside the mitochondria matrix, the only known organization unit of the mitochondrial genome containing mtDNA and associated architectural proteins, thus forming a distinct protein-DNA structure. Mammalian mitochondrial nucleoids are slightly ellipsoid with an average shape varying between slightly elongated (80×80×100 nm) [125] to truly ellipsoid (25×45×100 nm) [3, 24]. Because of its extranuclear localization, mtDNA was thought to follow a maternal pattern of inheritance with no paternal contribution [99, 222]. However, the discovery of Will Luo and colleagues presents...
an interesting conceptual breakthrough in that mtDNA can also be occasionally paternally inherited [149]. The number of mtDNA molecules per nucleoid is currently debated among several researchers. Recent studies support the idea of multiple mtDNA copies, ranging from 1.4 to 7.5 mtDNA per nucleoid [133], challenging the idea of a single copy of mtDNA per nucleoid [125]. However, the nucleoid morphology and size are independent of mtDNA copy number [125]. In mouse embryonic fibroblast cells (MEFs), an increase in mtDNA copy number induced by human TFAM overexpression leads to an increase in the total number of nucleoids per cell and cell size when compared with the wild-type MEFs, while the nucleoid size is fundamentally unaffected [125]. As revealed by proteomic analyses, a large number of potential mitochondria nucleoid-associated proteins have been identified and can be grouped into different functional classes. Apart from the key components of mitochondrial transcription (POLRMT, TFAM, TFB2M, TEFM) and replication (POLG, Twinkle, mtSSB) machinery, other important proteins, such as mitochondrial ribosomal proteins, proteases, chaperones, RNA-binding proteins, and RNA-processing proteins, have also been associated with the nucleoids. It was recently suggested that the mitochondrial nucleoid, not the mtDNA, is a unit of mitochondrial genome inheritance [68]. Nucleoids are semiregularly spaced within mitochondria to secure correct mtDNA transmission into the daughter cells at cell division [108, 173]. In addition, nucleoid-associated proteins, such as TFAM, have also been reported to influence mtDNA transmission [2, 113]. Knockdown of TFAM not only results in an abnormal nucleoid, but also causes asymmetric transmission of mtDNA into two daughter cells [113]. Thus, significant interest in nucleoid structure and its regulation has arisen to address the underlying mechanisms of mitochondrial diseases.

**Mitochondrial nucleoid-associated proteins**

As the most abundant architectural protein in the mitochondrial nucleoid, TFAM plays a major role in nucleoid structure. TFAM, a DNA-binding protein with tandem high-mobility group (HMG)-box domains, is highly conserved across species and present at a ratio of 1000 molecules per mtDNA, or 1 subunit per 16–17 bp of mtDNA [21]. When bound specifically to mtDNA promoters or nonspecifically throughout the mtDNA genome, TFAM fully coats and packages mtDNA into nucleoids by creating a stable U-turn with an overall bend of 180° [169]. TFAM is essential for the maintenance of mtDNA integrity, including mtDNA packaging [116, 170], transcription [196], replication [56], mtDNA copy number maintenance [101], and correct transcription [2, 113]. Growing evidence obtained from TFAM knockout mice has established a critical role of TFAM in the regulation of mitochondrial function and cardiac homeostasis. Inactivation of TFAM by Nkx2.5Cre in the mouse embryonic heart at E7.5 induces disrupted mitochondrial biogenesis and morphology, elevates ROS production, and depolarizes mitochondria, thereby causing embryonic lethality at E15.5 with marked myocardial wall thinning [248]. Other cardiomyocyte-specific TFAM knockout mouse models further characterized the effect of TFAM inactivation on mitochondrial cardiomyopathy with the development of dilated cardiomyopathy (DCM) [225]; [134, 202]. A decrease of TFAM expression has also been observed in several cardiac failure models with mitochondrial dysfunction [67, 100, 115, 131]. On the contrary, overexpression of TFAM exhibited therapeutic potential in heart failure, leading to the reduction of protease expression, ROS production, cytoplasmic calcium [128], and attenuated pathological hypertrophy [64] in cardiomyocytes. Cardioprotective effects were further confirmed in transgenic mouse models containing human TFAM gene, as evidenced by ameliorated mitochondrial deficiencies and improved cardiac function after myocardial infarction [102]. Although TFAM inhibition efficiently decreased the levels of mitochondria-encoded transcripts [104, 225], notably, overexpression of TFAM did not affect mtRNA levels, but rather mtDNA copy number [102]. These lines of evidence imply the presence of more complex regulatory mechanisms responsible for the association of TFAM, mtDNA, and mitochondrial homeostasis.

In fact, different mtDNA compaction from fully compacted nucleoids to naked DNA has been observed from the effect of physiological variation in TFAM on mtDNA ratios [60]. At high TFAM:mtDNA ratios, the nucleoid is fully compacted such that TFAM forms large, stable filaments on the DNA in a manner that blocks DNA melting through POLRMT and TWINKLE, thus preventing active mtDNA replication and transcription [60]. In support of this notion, a mild increase in TFAM levels in vivo (~twofold) leads to a proportional increase in mtDNA copy number [53], whereas forced overexpression of TFAM leads to mtDNA depletion [178]. Interestingly, when mtDNA was depleted in the presence of ethidium bromide (EB), knockdown of Lon (the regulator of TFAM) is unable to degrade TFAM, thereby causing a dramatic increase in the TFAM:mtDNA ratio, in turn resulting in the inhibition of mitochondrial transcription [156]. This indicates that the TFAM:mtDNA ratio may affect the number of compacted mtDNA and open mtDNA molecules.

Considering the role of TFAM as a histone-like protein in mtDNA packaging, it is plausible that TFAM also has modifications equivalent to those that occur on nuclear histones. In the nucleus, histones pack nDNA into nucleosomes forming chromatin. Modification of histones, including phosphorylation, methylation, acetylation, and ubiquitylation, strongly influences gene integrity [117]. Recently, nuclear-encoded transcription factors that regulate nuclear chromatin...
were found in the mitochondrial nucleoid, including MOF [32], members of the API family (c-Jun and JunD), CEBPB [20] and MEF2D [195]. Most importantly, MOF, a histone lysine acetyltransferase that remodels chromatin, was found to directly bind to mtDNA and inhibit mtDNA transcription [32]. Interestingly, TFAM levels were not obviously affected in these MOF-depleted cells. The discovery of TFAM-DNA-binding affinity, as regulated by acetylation and phosphorylation of TFAM [120], raises the question of whether TFAM is the acetyltransferase target of MOF in mitochondria. Moreover, TFAM was found to facilitate damaged mtDNA degradation by accelerating strand cleavage at abasic (apurinic/apyrimidinic, AP) sites [187], a ubiquitous form of DNA damage [141]. Considering the full coating of mtDNA by TFAM, these results suggest the ubiquitous nature of the TFAM-mediated abasic site containing mtDNA degradation.

For a long time, the higher-order organization of mtDNA in the nucleoid was considered far less regulated and complex owing to the lack of chromatin and histones. Intriguingly, recent analysis of DNase-seq and ATAC-seq experiments from multiple human and mouse samples revealed the formation of a conserved footprint during embryonic development, as an indication that mtDNA sites are increasingly occupied, but have low TFAM occupancy [19, 153]. Moreover, mtDNA sites with low occupancy of TFAM tend to adopt noncanonical nucleic secondary structures known as G-quadruplex sequences (GQs) [150]. GQs are notably conserved across species, and GQ motifs have been increasingly recognized to be associated with epigenetic reprogramming and chromatin remodeling [216]. GQs are widely present in mtDNA, as revealed by recent studies [55, 98], and GQ formation potentially regulates mitochondrial gene transcription and replication [55, 91, 167]. These studies further reflect the existence of the higher-order organization of protein-DNA structure in the mitochondrial genome in which the accessibility of mtDNA is potentially regulated by the TFAM:mtDNA ratio. Development of efficient experimental tools that allow selective detection of mitochondrial GQs or isolation of mitochondrial GQ structures could facilitate the discovery of novel mtDNA-binding proteins. Although important progress has been made in deciphering the molecular mechanisms of mito-nuclear communication in protein-DNA interaction, mitochondrial genome regulation is more complex and more regulated than once thought. Hence, it will be important for future studies to decipher the structure and organization of nucleoids and their specialized functions.

Mitochondrial genome regulation by noncoding RNAs

The discovery of noncoding RNAs (ncRNAs) has extended our knowledge of the molecular pathways involved in cardiac homeostasis. NcRNAs, as a large part of the noncoding genome, play various roles in cellular processes, rather than serving as a protein template. NcRNAs are classified into three types based on their localization and genetic origin: (1) cytoplasmic, nuclear-encoded ncRNAs; (2) mitochondria, nuclear-encoded ncRNAs and imported to the mitochondria; (3) mitochondria, mtDNA-encoded ncRNAs. Recently, ncRNAs have been increasingly found in the mitochondria and termed as mito-ncRNAs. These ‘mito-ncRNAs’ are ncRNAs located inside mitochondria, irrespective of their genetic origin [217]. Significant research has been aimed at unveiling how the ncRNAs are linked with their specific subcellular localizations and functions. These mito-ncRNAs can be grouped into microRNAs (miRNAs, 17–23 nucleotides (nt)), long noncoding RNAs (lncRNAs, > 200 nt), and circular RNAs (circRNAs). Cytoplasmic ncRNAs can modulate mitochondrial functions through a cytoplasmic mechanism. Next, we will review the role and function of particular mito-ncRNAs in cardiac homeostasis (see Table 1).

Mitochondrial miRNAs

As the most studied ncRNAs, miRNAs are short endogenous ncRNA species that are highly conserved. They recognize the complementary sequences of their message RNA (mRNA) target and form the RNA-induced silencing complex (RISC), thereby controlling gene expression post-transcriptionally by regulating mRNA degradation or translation [150]. However, miRNAs located in mitochondria (mito-miRs) are unique and distinguished from cytosolic miRNAs which are characterized by (1) unusual size (17–25 nt vs. average 22 nt length for the cytosolic miRNAs); (2) preferential genomic localization in mitochondrial gene clusters or close to mitochondrial genes (genomic position) [10, 11]; (3) unique structural features, such as containing no or small 3′UTR, short 3′ overhangs, stem-loop secondary structures [218], only one part of RNA-induced silencing complex (RISC), and multiple binding sites on mtDNA, but lacking 5′ cap [84]; and (4) unique thermodynamic features, e.g., minimal folding free energy (MEF) [10, 11]. These unique features of mito-miRs have been speculated to facilitate not only their entry into mitochondria but also their interaction with mtDNA transcripts.

The first evidence of miRNAs identified in mitochondria was described by Kren et al. in 2009 [123]. They found 15 nuclear-encoded mito-miRs isolated from adult rat livers as evidenced by Northern blot and stem-loop RT-PCR analyses. Similarly, Barrey et al. (2011) further confirmed the presence of miRNAs, including pre-miR-let7b, pre-miR-302a, and their corresponding mature miRNAs in mitochondria, as assessed by RT-PCR and in situ hybridization [12]. The presence of these pre-miRNAs in mitochondria might presuppose that the miRNA process occurs in mitochondria.
| Name | Targets | Function | Phenotype | References |
|------|---------|----------|-----------|------------|
| miR-1 | COX1 and ND1, MCU | Enhanced expression of mitochondrial COX1 and ND1 | Inhibition of miR-1 ameliorates cardiac hypertrophy/heart failure | [90], [109, 247] |
| miR-20 | Mfn2 | Mitochondrial fusion | Cardiac hypertrophy | [207] |
| miR-30c | Complex I (NDUFB8), complex II (SDHB), complex III (UQRC2), complex IV (MTOC1), and HSP60 | Mitochondrial OXPHOS | Dilated cardiomyopathy | [232] |
| miR-106a | Mfn2 | Mitochondrial fusion | Cardiac hypertrophy | [82] |
| miR-142-3p | SH2B1 | Mitochondrial membrane potential and mitochondrial density | Upregulation of miR-142-3p ameliorates cardiac hypertrophy | [142] |
| miR-485-5p | Mfn2 | Mitochondrial fusion | Cardiac hypertrophy | [253] |
| miR-497 | Sirt4 | Mitochondrial membrane potential and cytochrome c release | Overexpression of miR-497 inhibits cardiac hypertrophy | [238] |
| miR-34a | ALDH2 | Mitochondrial alcohol metabolism | Activation of miR-34a promotes cardiomyocyte apoptosis post-myocardial infarction | [57] |
| miR-28 | ALDH2 | Mitochondrial alcohol metabolism | Activation of miR-28 promotes cardiomyocyte apoptosis and ischemic injury | [136] |
| miR-762 | Complex I (ND2) | Mitochondrial ATP, ROS, and complex I enzymatic activity | Upregulation of miR-762 promotes cardiomyocyte apoptosis and ischemic injury | [241] |
| miR-181c | Complex IV (COX1) | Complex IV remodeling and ROS | Upregulation of miR-181c promotes ROS level in neonatal cardiomyocytes | [42] |
| miR-195 | Sirt3 | Regulation of mitochondrial function (mitochondrial acetylome) | Heart failure | [250] |
| miR-665 | GLP1R, cAMP signaling pathway | Complex I-IV | Inhibition of miR-665 ameliorates heart failure | [139] |
| miR-499 | Pdcd4, Pacs2, and Dyrk2 | Mitochondrial-related apoptosis (inhibition of Bid expression and mitochondrial translocation) | Upregulation of miR-499 protects H2O2-induced injury in cardiomyocytes | [224] |
| miR-3453p, miR-532, miR-690, miR-696 | Unknown | Unknown | These miRNAs are upregulated in the mitochondria of failing hearts | [227] |
| LncRNA LIPCAR | Unknown | Unknown | Circulating levels of mitochondrial LncRNA LIPCAR are downregulated early after acute myocardial infarction and upregulated during later stages and are associated with adverse cardiac remodeling and death, which predicts survival in heart failure patients | [126] |
| CircRNA MFACR | Targets miR-652-3p and the gene encoding mitochondrial membrane protein MTP18 | Mitochondrial fission and apoptosis | Downregulation of circRNA MFACR attenuates fission and heart failure post-myocardial infarction | [226] |
This would also mean that the mitochondrial genome can encode miRNAs, but this hypothesis needs further investigation. Given the well-characterized functional role of mitochondria in ATP production, it is not surprising that mito-miRNA-mediated OXPHOS activity is associated with heart diseases. Among these miRNAs involved in heart failure development, miR-1 is not only the most abundant miRNA in the heart, but it is also a muscle mitochondrial-enriched miRNA. The expression of miR-1 is downregulated in infarcted hearts [22], and it regulates mitochondrial ETC by directly regulating multiple proteins in the ETC networks, including cytochrome c oxidase subunit 1 (mt-COX1) and the mitochondrial gene NADH dehydrogenase subunit 1 (mt-ND1) [251]. Notably, in this model, miR-1 acts as a mitochondrial translation activator whereby AGO2 can bridge the ribosome (12SrRNA) to the miR-1-bound mtRNA to activate translation [251]. MiR-1 is also involved in mitochondrial Ca²⁺ overload through targeting the mitochondrial calcium uniporter (MCU) mRNA and inhibiting its translation, thereby leading to cardiac hypertrophy [109, 247]. Furthermore, miR-181c, as the mitochondrial-located miRNA in cardiomyocytes [42], was shown to cause mitochondrial and cardiac dysfunction [41, 42]. Through their ability to modulate mitochondrial function, metabolism and dynamics, mito-miRs have been implicated in cardiac homeostasis, as summarized in Table 1.

Mitochondrial IncRNAs

Although most studies have focused on miRNAs in cardiac homeostasis, research has also explored the function and biological significance of IncRNAs in cardiac homeostasis. LncRNAs, as a new class of regulatory ncRNAs, are longer than 200 nt and evolutionarily less conserved compared to miRNAs. The first evidence of mito-IncRNA was described by Beckham et al. in 2011 [182]. They discovered that three IncRNAs (IncND5, IncND6, and IncCytb) specifically produced by the mitochondrial genome and their accumulation in mitochondria is regulated by MRPP1. Mitochondrial-encoded IncRNAs are divided into three categories: (1) simple antisense mitochondrial DNA-encoded IncRNAs (e.g., IncND5, IncND6, IncCytb, IncRNA, and MDL1) [66, 159, 182], (2) Chimeric mtDNA-encoded IncRNAs (e.g., SncmtRNA, ASncmtRNA-1, and ASncmtRNA-2) [25, 129, 220], and (3) putative mtDNA-encoded IncRNAs (e.g., LIPCAR) [47, 126, 242]. Interestingly, only limited evidence supports the presence of nuclear-encoded IncRNAs in mitochondria owing to the unresolved mitochondrial import mechanism. Among the IncRNAs implicated in cardiac dysfunction, only one mito-IncRNA has been reported. The circulating mitochondrial IncRNA uc022bqs.1 (LIPCAR) was found to be upregulated in the late stages of patients who developed left ventricular remodeling post-myocardial infarction. With another independent cohort of 344 patients with chronic heart failure, the level of LIPCAR was upregulated independent of pathogenesis. Most importantly, higher LIPCAR levels were significantly associated with a higher risk of cardiovascular death [126]. The importance of mito-IncRNAs in the pathogenesis of cardiomyopathy was further supported by recent studies that reveal a distinct relative abundance of dysregulated IncRNA of mitochondrial origin in failing hearts. These IncRNAs encoded by mtDNA constitute the majority (71%) of the total IncRNA pool of the human left ventricle [242]. Hence, it not clear if mito-IncRNAs detected in circulation come from heart. Moreover, these IncRNA profiles can better distinguish samples of cardiomyopathy with different etiology/mechanical circulatory support than either miRNA or mtRNA profiles. Thus, mito-IncRNAs could be useful for the detection and diagnosis of disease subtypes in the future.

Mitochondrial circular ncRNAs

As the least investigated ncRNAs, circular ncRNAs (cIRRNAs) present a closed circle structure resulting from a covalent bond between their 3′ and 5′ ends. Although the function of more than 99% of circRNAs remains unclear, recent studies have revealed their roles in miRNA and RBP sponging, transcriptional and post-transcriptional regulation, protein templates, and immune response [158, 219, 234]. The first evidence of circRNAs in mammalian mitochondria was described by Gao et al. in 2018. Three mitochondria-encoded circRNAs were found, but their functional information was not further investigated [66]. In 2019, Liu et al. further identified hundreds of circRNAs encoded by the mitochondrial genome in both human and murine cells. Strikingly, they first found that two circRNAs encoded by the mitochondrial genes ND1 and ND5 could facilitate the mitochondrial entry of nuclear-encoded proteins through the TOM40 complex [144]. This discovery broadened our understanding of the critical roles of nuclear-encoded protein mitochondrial shuttling. Although mtDNA-encoded circRNAs have been identified [110, 144, 191], the functions of mitochondria-localized circRNAs (mito-circRNAs) are largely unknown as a result of the special mitochondrial bilayer structure and highly negative membrane potential [228]. Recently, mito-circRNAs have attracted extensive attention in human diseases. A circulating mito-circRNA, mCOX2, was found to be highly expressed in chronic lymphocytic leukemia (CLL) patients and significantly associated with its progression and prognosis [236]. Most recently, a mitochondrial-enriched circRNA, ATP5B regulator (SCAR), was screened by circRNA expression profile analysis of patients with nonalcoholic steatohepatitis (NASH). In patients with NASH, SCAR was downregulated in liver fibroblasts, an outcome closely correlated with disease...
progression. Overexpression of SCAR in NASH fibroblasts blocked mPTP opening, inhibiting mitochondrial ROS output and subsequent fibroblast activation. In mice fed a high-fat diet, specific delivery of SCAR to liver fibroblasts using mitochondria-targeting nanoparticles alleviates cirrhosis and insulin resistance accompanied with NASH [252].

Although no direct evidence currently supports the association between mito-cirRNAs and cardiac homeostasis, one circRNA (MFACR) has been reported to directly target miR-652-3p and promote mitochondrial fission and cardiomyocyte apoptosis through blocking the translation of MTP8 [226].

**Potential impact of ncRNA on mitochondrial R-loop formation**

The ncRNAs are increasingly found in mitochondria, but their functions remain largely unknown. Recently, R-loop in mitochondria (termed as mtR-loop) was surprisingly detected [244] and associated with mitochondrial genome stability [199]. R-loops are three-stranded nucleic acid structures comprising a RNA:DNA hybrid and an unpaired single-stranded DNA. In general, R-loops occur transiently during transcription, playing essential physiological functions. However, when R-loops occur accidentally in a nonscheduled manner, they become a potential source of cellular pathological R-loop. A growing body of evidence has connected these pathological R-loops to the pathophysiology of diseases [81], including DNA repair, replication, activation of tumor-promoting genes [18, 21, 121, 201], and immune response [152]. Recent studies showed that IncRNAs can interact with DNA and form R-loop structures [33, 80]. In addition, Fan et al. reported that nuclear-derived microRNA (miR-2392) can be shuttled into mitochondria and hybridize with mtDNA, leading to downregulation of the genes responsible for oxidation phosphorylation, metabolic reprogramming, and chemoresistance in cancer [58]. These pioneering studies suggest that mitochondrial ncRNA may regulate mitochondrial transcription through the formation of R-loops.

An important question is whether ncRNAs can interact with DNA to form R-loop structures. To address this, it is necessary to establish an assay suitable for R-loop mapping in mitochondria. DRIP-seq is the first and widely used approach for genome-wide mapping of R-loop in vitro by harnessing S9.6 antibody for chromatin immunoprecipitation [73]. However, the resolution for DRIP-seq is low (around several kilobases) from the fragmentation of genomic DNA by restriction enzyme and thus cannot satisfy the investigation of R-loop in mitochondria with only 16.5 kb mtDNA. In addition, the specificity of S9.6 has been recently questioned since, for example, it also binds dsRNA/dsDNA [177], leading to false positivity. RNaseH1 is an endonuclease which displays high affinity of RNA–DNA hybrids and cleaves the RNA in RNA:DNA hybrids.

Recently, the Xiang-dong Fu lab developed an R-ChIP [33, 34] approach using catalytically inactive RNaseH1 (point mutation in the catalytic site (D210N)) with the addition of a nuclear localization signal (NLS) in the N-terminus and a tagged V5 sequence at the C-terminus. Followed by sonication, instead of restriction enzyme, as in DRIP-seq, chromatin immunoprecipitation (anti-V5 antibody), library preparation and sequencing, this approach can detect genome-wide R-loops in the nucleus with high resolution of around 200–300 bp. We propose that this method is ideal for R-loop studies in mitochondria when minor modifications are made, such as replacement of NLS with the mitochondrial localization signal (MLS), to direct the RNaseH1 (D210N) into mitochondria. Furthermore, the resolution for mitochondrial R-loop could be further increased using exo-nucleases, rather than sonication, during the fragmentation step, which is similar to the ChIP-nexus protocol [89], to obtain the “footprint” of RNaseH1 (D210N). Such high-resolution mapping can help locate the actual R-loop structures in the “busy” mitochondrial genome harboring 37 genes and many regulatory elements within 16.5 kb DNA (Fig. 4).

Emerging evidence suggests that mitochondrial damage-associated molecular patterns (DAMPs) are the major activators of inflammation when leaked from stressed mitochondria, which then facilitates cardiac dysfunction [77, 111, 174, 205]. Of the known mitochondrial DAMPs, mitochondrial nucleic acids, such as mtDNA, have garnered the most attention [23, 230]. Cardiomyocyte-derived mtDNA, having escaped from defective mitophagy, could trigger inflammation, thereby inducing myocardocyte and dilated cardiomyopathy [171]. Although numerous independent studies have supported the inflammatory nature of ‘cell-free mtDNA’ [45, 46, 213, 246], this set of experiments does not distinguish between the presence of double-strand DNA (dsDNA, mtDNA) versus R-loop. Thus, the strategies used to characterize the mtR-loop are important and will ultimately enable novel therapeutic regimens for disease intervention where R-loop regulation is dysfunctional.

Recently, a class of small proteins, or peptides (micropeptides), encoded by short open reading frames (sORFs) within ncRNAs (e.g., IncRNAs), are now being recognized for their fundamental biological importance in ion channel modulation [6], cell signaling [155] and RNA regulation [38]. Most importantly, these micropeptides are surprisingly enriched in mammalian mitochondrial proteome, accounting for 5% of its proteins [27]. One example is mitoregulin (MOXI, MPM), a muscle- and heart-enriched 56 amino acids encoded by mito-IncRNA (linc00116) [36, 140, 151, 204]. Mitoregulin localizes within inner mitochondrial membrane, binds cardiolipin, and influences protein complex assembly and/or stability, thereby regulating mitochondrial respiratory...
(super) complex formation and activity, fatty acid oxidation, TCA cycle, and Ca^{2+} dynamics, putatively explaining how mitochondrial homeostasis is regulated by ncRNAs.

### Three-dimensional (3D) organization of mitochondrial nucleoid

Recent mapping technologies have revealed that the eukaryotic genome in the nucleus does not exist as a linear molecule, but instead is packaged into a 3D structure with higher-order organization. The 3D chromatin organization in the nucleus enables the regulation of gene expression during cardiac development in both physiological processes in health and pathogenesis of disease [16, 188]. As discussed above, mtDNA is compacted into a nucleoprotein complex, forming a higher-order chromatin-like organization for transcription regulation. Hence, it would be interesting to unravel the 3D architecture of mitochondrial nucleoid and examine the existence of higher-order architecture in the mitochondria similar to topologically associating domains (TADs) in the nucleus.

In the past few years, 3D genome approaches (e.g., Hi-C) in the nucleus have used restricted enzymes (e.g., HindIII [138], MboI [183], and DpnII [14]) for chromatin fragmentation, followed by chromatin ligation. The resolution of Hi-C depends on the frequency of the restricted enzyme recognition sites and the sequencing depth. In most publications, the maximal resolution of Hi-C is around several kilobases on average in the genome. Considering the distribution of restricted enzyme recognition sites on the mitochondrial genome with small size (about 16.5 kb), the conventional Hi-C approach is not suitable for the dissection of 3D architecture of the mitochondrial nucleoid. This calls for the development of novel techniques that enable us to examine the interaction of regulatory elements in mitochondria and also examine the existence of TAD-like structures in the nucleoid. Recently, two breakthrough publications demonstrated that a new technique called micro-C can detect micro-scale genome organization up to single-nucleosome resolution in human [97, 124]. Unlike Hi-C using restricted enzymes, micro-C uses MNase which first acts as an endonuclease by nicking the DNA on the A/T site and then functions as an exonuclease to nibble the DNA until it meets the protein “block” (e.g., histone or transcription factor) [206]. In the micro-C method, the MNase-digested nucleosomes are kept for downstream proximity-ligation reaction. However, mitochondria lack nucleosomes, making this protocol unusable in mitochondrial samples. Here, we propose modifications of micro-C that would make it applicable to the mitochondrial genome. Currently, protein A/G-conjugated MNase is employed in the CUT and RUN method [200] to capture histone or transcription factor binding sites. In the CUT and RUN method, a primary antibody is added to the nucleus after cell permeabilization to target the chromatin. Then protein A/G-MNase is added into the nucleus. It recognizes the sites with primary antibody binding and can, therefore, cut chromatin enriched with the specific protein, i.e., the target of primary antibody. Since TFAM
is thought to be the major constituent for mitochondrial nucleoid organization with the capacity of DNA bending and compaction, the TFAM antibody and protein A/G-MNase could be used to isolate the TFAM-DNA complex, followed by ligation and other steps in the micro-C protocol. This modified micro-C approach would allow for dissection of the TFAM-centric 3D architecture of the mitochondrial nucleoid (Fig. 5A). In addition to TFAM, other nuclear-derived chromatin modifiers/transcription factors (e.g., MOF [32], AP-1 [20], CEBPB [20], and MEF2D [195]) are reported to be involved in the regulation of mitochondrial transcription, suggesting their potential contributions in mitochondrial nucleoid organization. Thus, for an unbiased discovery of the 3D architecture of mitochondrial nucleoid, a recent approach called genome architecture mapping (GAM) could be utilized [13]. GAM was developed to measure the 3D genome organization via sequencing the DNA from a large quantity of nuclear sections and statistical modelling. Similarly, GAM would be performed in mitochondria. Through cutting thinner slices, it could be possible to obtain a high-resolution map of 3D architecture of mitochondrial nucleoid (Fig. 5B). In addition, compared to proximity ligation-based approaches, such as Hi-C, which can only detect binary interactions, i.e., one locus to one locus, GAM is a ligation-free approach and thus can identify the transcription hub, or interactome of multiple regulatory elements, in the mitochondrial genome. These approaches would help us to demystify the existence of TAD (topologically associating domains)-like structures in mitochondria and further unveil the transcription regulation of metabolic reprogramming in health and disease (Fig. 5C).

Emerging regulators for 3D architecture of mitochondrial nucleoid

N6-Methyldeoxyadenosine (6 mA) is the major DNA modification in prokaryotes [215]. However, whether 6 mA exists in mammalian genomes remains a top controversial issue in epigenetic research. This mainly results from the low abundance and large variation of 6 mA distribution in different mammals and different tissues (0.0001% ~ 1%) [93, 122, 143, 237, 239], raising several questions about its biological functions. Through ultra-high performance liquid chromatography coupled to triple quadrupole mass spectrometry (UHPLC-QQQ-MS/MS), immunofluorescence and dot blot experiment, the Chuan He lab found that 6 mA is highly enriched in human mtDNA and that the abundance is 1300-fold higher than that of genomic DNA in a human liver cancer cell line [85]. The deposition of 6 mA on mtDNA is orchestrated by mitochondria-localized METTL4, a putative mammalian methyltransferase, and the authors showed that 6 mA impaired DNA binding and bending mediated by TFAM, leading to transcriptional repression of mitochondria. Furthermore, under hypoxia, METTL4 and m6A are significantly elevated compared to normoxia. These data suggest that the METTL4/6 mA could sense and respond

---

**Fig. 5** Novel strategies to dissect 3D genome structure of the mitochondrial nucleoid. **A** Modified micro-C approach to map TFAM-centric 3D genome structure of mitochondria (pAG-MNase: protein A/G beads conjugated with MNase); **B** Genome architecture mapping (GAM) approach to map global 3D genome structure of mitochondria via cryosectioning, sequencing of DNA from individual slices and computational analysis (co-segregation frequency); **C** 3D genome mapping of mitochondrial nucleoid can examine the existence of topologically associating domains (TADs) and transcriptional hub (interaction of multiple regulatory elements) in the mitochondrial nucleoid.
to metabolic stress via modulation of the 3D organization of mitochondrial nucleoid [85]. A previous report demonstrated that the abundance of 6 mA was highly dynamic during the embryonic development of Drosophila (~0.07% at the ~0.75 h. vs. ~0.001% at the 4 h) [249]. Thus, whether 6 mA on mtDNA is highly dynamic during human embryonic development, resulting in dynamic alterations of 3D architecture of mitochondrial nucleoid and metabolic reprogramming, deserves future investigation.

Interestingly, a recent study suggested that mitochondrial nucleoids might be formed by phase separation. The authors found that the combination of TFAM-mtDNA is sufficient to form gel-like droplets in vitro, which are affected when intrinsically disordered regions (IDR) of TFAM are mutated [61]. This is in line with previous studies from the Richard Young lab, showing that IDR is essential for transcription factor coactivators BRD4 and MED1 to form droplets (compartmentalization) and, thus, facilitate gene transcription [189]. The authors also showed that enlarged phase-separated mitochondrial nucleoids could be observed in the premature ageing disease Hutchinson-Gilford Progeria Syndrome (HGPS) in association with TFAM and that this is linked to impaired mitochondrial oxidative phosphorylation and ATP regeneration [61]. However, the underlying mechanisms for enlarged phase-separated mitochondrial nucleoids in HGPS remain elusive. Besides the potential alteration of IDR in TFAM, the impact of 6 mA on phase separation would be another potential mechanism to be validated. Recent study has uncovered that N6-Methyladenosine (m6A) on RNA can enhance phase separation [186]. Therefore, the potential of 6 mA affecting 3D architecture of mitochondrial nucleoid via modulation of phase separation would be an intriguing research direction in the future.

Mitochondrial retrograde signaling and its potential impact on nuclear 3D chromatin architecture

Hierarchical 3D genome organization includes multiscale structural units of chromosome territories, compartments, topologically associating domains (TADs), which are often demarcated by such chromatin architectural proteins as CCCTC-binding factor (CTCF) and cohesin, and chromatin loops [254]. However, the mechanisms underlying the formation and function of nuclear chromatin architecture have not been fully resolved. Notably, mitochondria can generate a wide range of retrograde signals through which they regulate nuclear gene expression. Here we discuss the implication of mitochondrial retrograde signals for 3D genome organization and propose possible strategies to test this.

**Mitochondrial-derived ncRNAs**

Although mitochondrial-generated ncRNAs (e.g., ASnc-mtRNA-1 and ASncmtRNA-2) are translocated into the nucleus and associated with perinuclear chromatin [62, 129], their functions in transcription regulation remain largely unknown. Recently, four approaches, termed global RNA Interactions with DNA by deep sequencing (GRID-seq) [137], Chromatin-Associated RNA sequencing (ChAR-seq) [15], HiChIRP [164], and RNA in situ conformation sequencing (RIC-seq) [26], have identified that chromatin-associated RNAs (CARs) are largely involved in long-range chromatin interactions. For example, ncRNA can bind to the MYC enhancer and MYC promoter and interact with the RNA-binding protein hnRNPK, while the oligomerization of hnRNPK can juxtapose the enhancer to MYC promoter and promote MYC transcription [26]. In addition, ncRNA Thy-moD facilitates CTCF/cohesin-dependent loop extrusion and repositions Bcl11b enhancer from nuclear periphery proximal to Bcl11b promoter, leading to transcription activation of Bcl11b and T cell commitment [106].

In addition to juxtaposing enhancers and promoters in the 3D genome, CARs can also modulate chromatin topology. For example, YY1 is an emerging architectural protein for orchestrating enhancer-promoter interaction [229], and its localization on DNA is facilitated by direct binding with CARs [198]. Furthermore, insulated neighborhoods are chromatin topological structures (loops) formed by CTCF-CTCF homodimers [50] and the major structural components of TADs, the boundaries of which are enriched by CTCF [92]. CTCF can bind large numbers of ncRNA, and a recent report from Danny Reinberg’s lab indicated that mutation of the RNA-binding region of CTCF could disrupt CTCF loop formation, resulting in transcriptional inactivation [190]. This means that the functions of ncmtRNAs in CTCF formation could be further delineated in the future. In addition, whether nuclear-localized ncmtRNAs regulate genome compartment (e.g., heterochromatin) formation and maintenance through m6A-mediated phase separation [186] will be another intriguing topic for further investigation (Fig. 6A).

**Mitochondrial-derived peptides or truncated proteins**

Although the vast majority of mitochondrial proteins are encoded in the nucleus, some new classes of peptides were recently discovered with mitochondrial origins. These mitochondrial-derived peptides (MDPs) are the peptides encoded by small open reading frames (ORFs) within mtDNA (mtORF) [223]. At present, three types of MDPs have been identified, including 16S rRNA-encoded Humanin (HN), 12S rRNA-encoded MOTS-c and 16S rRNA-encoded small humanin-like peptides (SHLP1-6). As the first MDP, HN was discovered by Hashimoto and his colleagues in the undamaged brain of a patient with Alzheimer’s disease [86]. HN structure and function has been well studied, and various HN analogs are believed to have protective effects.
against cardiovascular diseases [78] in addition to neuronal diseases [132, 208]. Administration of an analog of HN (the serine at position 14 replaced by glycine, termed as HNG) prior to, or at the time of, reperfusion has been shown to play a cardioprotective role in a mouse model of myocardial ischemia and reperfusion, which potentially improved cardiomyocyte survival and attenuated apoptosis [166]. Similarly, high-doses of HNG applied during the ischemic period also exerted cardioprotection, leading to significantly decreased cardiac arrhythmia, myocardial infarct size, apoptosis, cardiac mitochondrial dysfunction, and left ventricular dysfunction [209]. Under pathologic conditions, increased ROS is detrimental to cardiomyocytes [179]. Specifically, complexes I and III of the ETC are major sites of ROS production in cardiac mitochondria [203]. Recent studies confirmed the contribution of HNG to reduced ROS production in damaged cardiac mitochondria. Administration of HNG both activated the Abl- and Arg-dependent cellular defense system and decreased complex I activity [210]. Additionally, cardioprotective effects of HNG were recently found in aged hearts through preventing myocardial fibrosis, mPTP opening, and apoptosis [181]. Further studies also show the relationship between MDPs and coronary microvascular dysfunction (CMD), which are both risk factors for cardiac dysfunction. In the cohort of patients with CMD, lower levels of HN were observed in circulating blood [231]. Another independent study also found that the levels of HN and MOTS-c in circulating blood of patients with impaired endothelial function were lower than those of the control groups [181]. These results suggest that HN or MOTS-c has significant potential as a new marker to diagnose CMD or identify potential therapeutic targets.

Recent research has reported that MOTS-c translocates from mitochondria into the nucleus in response to glucose restriction, leading to retrograde signaling [118, 184]. MOTS-c can bind to nuclear genomic DNA and interact with transcription factor Nrf2 to activate gene transcription, resulting in increased cellular resistance to metabolic stress [118]. Reynolds et al. in 2021 found that MOTS-c is an exercise-induced mitochondrial-encoded regulator of muscle homeostasis which can regulate the nuclear genes involved in metabolism and proteostasis, thereby significantly improving physical performance in young, middle-aged, and old mice [184]. Moreover, administration of MOTS-c at late-life (23.5 months) can increase the lifespan of old mice. These landmark studies provided a new paradigm for understanding the impact of MDPs on nuclear gene regulation in metabolic reprogramming.

In addition, a recent study surprisingly found that calpain can cleave full-length junctophilin-2 to covert it from a cardiac structural protein into a transcription factor, leading to its translocation from the cell membrane into the nucleus for cardiac protection [83]. As calpain is not only localized in cytosol, but also in mitochondria [9, 107, 175, 197],

---

**Fig. 6** Novel directions for mito-nucleus crosstalk studies in cardiac diseases: mitochondrial retrograde signaling and its potential impact on nuclear 3D chromatin architecture. A Mitochondrial-derived peptides or truncated proteins (cleaved by mitochondrial calpain) that moonlight as transcription factors to act on nuclear regulatory elements and induce their interactions for transcription regulation; B Mitochondrial-derived ncRNAs regulate nuclear 3D genome organization via association of perinuclear chromatin, orchestration of insulated neighborhoods (binding on architecture proteins CTCF and YY1), and facilitation of enhancer-promoter interaction (one binding on enhancer/promoter; two interacting with RNA-binding protein hnRNPK; three oligomerization of hnRNPK to juxtapose enhancer and promoter); C Loop extrusion is mediated by Cohesin and NIPBL through ATP hydrolysis, while the source of ATP, whether mitochondrial, nuclear pool by hydrolysis of poly(ADP-ribose) to ADP-ribose, or both, remains to be determined in the future.
future work is needed to delineate the proteins that shuttle from mitochondria into nucleus after mitochondrial-calpain cleavage and subsequently regulate chromatin architecture (Fig. 6B).

Mitochondrial-derived ATP could be essential fuel for the establishment of topological domains in the nucleus

The loop extrusion model is the most popular model for CTCF loop, insulated neighborhood formation and TADs [63, 92]. This model postulates that cohesin complex is loaded onto DNA by physical stimulation and reels in DNA to form loops. Loop extrusion can then be stopped when cohesin meets convergent CTCF sites. Recent studies have provided direct evidence in support of this model and have shown conclusively that cohesin extrudes DNA loop in an ATP hydrolysis-dependent manner [44, 119]. Previously, it was well recognized that ATP is generated only from mitochondria. However, this prevailing “dogma” was recently challenged, showing that ATP can also be generated in the nucleus via the hydrolysis of poly (ADP-ribose) to ADP-ribose and that this was shown to be essential for hormone-induced chromatin remodeling in a breast cancer cell line [235]. This raises several questions. First, is the “nuclear pool” only confined to breast cancer cells or present in all mammalian cells? Second, what is the source of ATP for loop extrusion, mitochondria, nucleus or both? Most mitochondrial diseases are caused by mutations of mtDNA, leading to defects in the OXPHOS system and reduction of ATP production [79] and cardiac involvement [233]. Therefore, third, does ATP reduction caused by mutations of mtDNA cause global loss of CTCF loops and transcriptional dysregulation?

Precise mtDNA editing was long deemed as impossible. However, a recent study developed a novel approach based on RNA-free DddA-derived cytosine base editors (DdCBEs), which can catalyse nucleotide conversions in human mtDNA with high target specificity [160]. Based on this technology, human iPSC-derived cardiomyocytes from patients with diseases like hypertrophic cardiomyopathy [135], before and after mtDNA editing (rectification of mtDNA mutation), can be generated and used to study disease mechanisms. For example, by performing high-resolution 3D genome mapping (e.g., in situ Hi-C or CTCF/Cohesin-centric in situ ChIA-PET [17]; HiChIP [165]; or PLAC-seq [59]) in the nucleus from those cells, it is possible to assess the impact of mtDNA mutation on 3D genome reprogramming in the nucleus of cardiomyocytes (Fig. 6C). Such studies would give completely fresh insight into the pathogenesis of mitochondrial diseases with cardiac involvement and reveal the plausible impact of mtDNA mutation on transgenerational inheritance of abnormal nuclear genome topology in patients.

Closing remarks

A growing body of research has established that mitochondria serve as the core component of the cell signaling pathway. Unveiling the mechanisms that control how mitochondrial nucleoid components orchestrate cell responses to stressful stimuli is essential for a better understanding of the transition between cardiac health and disease. Researchers have only just begun to understand how communication between mitochondria and nucleus are coordinated in response to metabolic stress. In this review, we have taken a fresh perspective on 3D genome architecture and its role in the crosstalk between mitochondria and nucleus. We believe that studies designed to demystify the overlooked questions delineated in this review will provide a foundational understanding of the regulation of metabolic reprogramming and its translation into clinical benefits in the future.

Acknowledgements This work is supported by a Cancer Research UK Career Development Fellowship Grant to Dr. Siim Pauklin (C59392/A25064; Royal Society, UK), the Clarendon Fund and St. Edmund Hall Scholarship, UK, to Dr. Yuliang Feng (SFF1920_CB_MSD_759707), the USA National Institutes of Health grants HL136025-01A1 and HL143490-01A1 to Dr. Yigang Wang, and an American Heart Association Career Development Award (20CDA35310176) to Dr. Wei Huang. Dr. Sadayappan has received support from National Institutes of Health grants (R01 HL130356, R01 HL105826, R01 AR078001 and R01 HL143490), American Heart Association, Cardiovascular Genome-Phenome Study (15CVGPSD27020012), Catalyst (17CCRG33671128), Institutional Undergraduate Student (19UFEL34380251) and Transformation (19TPA34830084) awards, the PLN Foundation (PLN crazy idea) awards, as well as AstraZeneca, MyoKardia, Merck and Amgen.

Author contributions Y.F and W.H. conceived and drafted the manuscript. C.P. X.L, S.S., and Y.W. edited the manuscript. S.P. edited and finalized the manuscript. All authors read and approved the manuscript for submission.

Data availability Not applicable.

Declarations

Conflict of interest Dr. Sadayappan provides consulting and collaborative research studies to the Leducq Foundation (Transatlantic Network 18CVD01, PLN-CURE), Red Saree Inc., Greater Cincinnati Tamil Sangam, AstraZeneca, MyoKardia, Merck and Amgen, but such work is unrelated to the content of this article. No other disclosures are reported.

Consent to participate This article does not contain any studies with human or animal subjects performed by the any of the authors.

Consent for publication Not applicable.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Ahola S, Isohann P, Euro L, Brilhante V, Palotie A, Pihko H, Lonnqvist T, Lehtonen T, Laine J, Tyynismaa H, Suomalainen A (2014) Mitochondrial EFTs defects in juvenile-onset Leigh disease, ataxia, neuropathy, and optic atrophy. Neurology 83:743–751. https://doi.org/10.1212/WNL.0000000000000716
2. Alam TI, Kanki T, Muta T, Ukaji K, Abe Y, Nakayama H, Takio K, Hamasaki N, Kang D (2003) Human mitochondrial DNA is packaged with TFAM. Nucleic Acids Res 31:1640–1645. https://doi.org/10.1093/nar/gkg251
3. Alan L, Spacek T, Jezek P (2016) Delaunay algorithm and principal component analysis for 3D visualization of mitochondrial DNA nucleoids by Biplane FPALM/iSTORM. Eur Biophys J 45:443–461. https://doi.org/10.1007/s00249-016-1114-5
4. Alila-Fersi O, Tabebi M, Maalej M, Belguith N, Keskes L, Mkaouar-Rebai E, Fakhfakh F (2018) First description of a novel mitochondrial DNA deletion and depletion in family with severe dilated mitochondrial cardiomyopathy. Biochem Biophys Res Commun 497:1049–1054. https://doi.org/10.1016/j.bbrc.2018.02.173
5. Alston CL, Ceccatelli Berti C, Blakely EL, Olahova M, He L, McMahon CJ, Olpin SE, Hargreaves IP, Nolli C, McFarland R, Goffrini P, O’Sullivan MJ, Taylor RW (2015) A recessive homozygous p.Asp92Gly SDHD mutation causes prenatal cardiomyopathy and a severe mitochondrial complex II deficiency. Hum Genet 134:869–879. https://doi.org/10.1007/s00439-015-1568-z
6. Anderson DM, Anderson KM, Chang CL, Makarewich CA, Nelson BR, McNally JR, Kasaragod P, Shelton JM, Liou J, Patel-Ruby S, Robinson P, Cervenka J, McMichael J, El-Armouche B, Boxer SL, Nolli C, McFarland R, Gofperini P, O’Sullivan MJ, Taylor RW (2015) A micropeptide encoded by a putative long noncoding RNA regulates muscle performance. Cell 160:595–606. https://doi.org/10.1016/j.cell.2015.01.009
7. Andreu AL, Checcarelli N, Iwata S, Shanske S, DiMauro S (2000) A missense mutation in the mitochondrial cytochrome b gene in a revisited case with histiocytoid cardiomyopathy. Pediatr Res 48:311–314. https://doi.org/10.1203/00006450-2000000900-00008
8. Antonicka H, Mattman A, Carlson CG, Glerum DM, Hoffbaur KC, Leary SC, Kennaay NG, Shoubridge EA (2003) Mutations in COX15 produce a defect in the mitochondrial heme biosynthetic pathway, causing early-onset fatal hypertrophic cardiomyopathy. Am J Hum Genet 72:101–114. https://doi.org/10.1086/345489
9. Arrington DD, Van Vleet TR, Schnellmann RG (2006) Calpain 10: a mitochondrial calpain and its role in calcium-induced mitochondrial dysfunction. Am J Physiol Cell Physiol 291:C1159–1171. https://doi.org/10.1152/ajpcell.00207.2006
10. Bandiera S, Mategot R, Girard M, Demongeot J, Henrich-Cauze A (2013) MitomiRs delineating the intracellular localization of microRNAs at mitochondria. Free Radic Biol Med 64:12–19. https://doi.org/10.1016/j.freeradbiomed.2013.06.013
11. Bandiera S, Ruberg S, Girard M, Cagnard N, Hanein S, Chretien D, Munnich A, Lyonnert S, Henrich-Cauze A (2011) Nuclear outsourcing of mitochondrial RNA interference components to human mitochondria. PLoS ONE 6:e20746. https://doi.org/10.1371/journal.pone.0020746
12. Barrey E, Saint-Auret G, Bonnambyl D, Boyer O, Gidrol X (2011) Pre-microRNA and mature microRNA in human mitochondria. PLoS ONE 6:e20220. https://doi.org/10.1371/journal.pone.0020220
13. Beagrie RA, Scialdalone A, Schueler M, Kraemer DC, Chotalia M, Xie SQ, Barbieri M, de Santiago I, Lavitas LM, Branco MR, Fraser J, Dostie J, Game L, Dillon N, Edwards PA, Nicodemi M, Pombo A (2017) Complex multi-enhancer contacts captured by genome architecture mapping. Nature 543:519–524. https://doi.org/10.1038/nature21411
14. Belaghi A, Dekker J, Gibbuc JS (2017) Hi-C 2.0: an optimized Hi-C procedure for high-resolution genome-wide mapping of chromosome conformation. Methods 123:56–65. https://doi.org/10.1016/j.ymeth.2017.04.004
15. Bell JC, Jukam D, Teran NA, Risca VI, Smith OK, Johnson WL, Skotheme JM, Greenleaf WJ, Straight AF (2018) Chromatin-associated RNA sequencing (ChAR-seq) maps genome-wide RNA-to-DNA contacts. Elife 7:e27024. https://doi.org/10.7554/ eLife.27024
16. Berterio A, Rosa-Garrido M (2020) Three-dimensional chromatin organization in cardiac development and disease. J Mol Cell Cardiol 151:89–105. https://doi.org/10.1016/j.yjmcc.2020.11.008
17. Bertolini JA, Favaro R, Zhu Y, Pagin M, Nyan CY, Wong CH, Tjong H, Vertumn MW, Martinez V, Barone C, Mariani J, Cardozo MJ, Tabanera N, Zambelli F, Mercurio S, Ottolenghi S, Robson P, Cereghino JP, Bovolenta P, Pavesi G, Guillemot F, Nicola SK, Wei CL (2019) Mapping the global chromatin connectivity network for Sox2 function in neural stem cell maintenance. Cell Stem Cell 24(462–476):e466. https://doi.org/10.1016/j.stem.2019.02.004
18. Bhatia V, Barroso SI, Garcia-Rubio ML, Tumini E, Herrera-Moyano E, Aguilera A (2014) BRCA2 prevents R-loop accumulation and associates with TREX-2 mRNA export factor PCID2. Nature 511:362–365. https://doi.org/10.1038/nature13374
19. Blumberg A, Dango CG, Kundaje A, Mishmar D (2018) A common pattern of DNAse I foot-printing throughout the human mtDNA unveils clues for a chromatin-like organization. Genome Res 28:1158–1168. https://doi.org/10.1101/gr.234049.117
20. Blumberg A, Sai Sailaja B, Kundaje A, Levin L, Dadon S, Shmorak S, Shaulian E, Meshorer E, Mishmar D (2014) Transcription factors bind negatively selected sites within human mtDNA genes. Genome Biol Evol 6:2634–2646. https://doi.org/10.1093/gbe/evu210
21. Bogenhagen DF (2012) Mitochondrial DNA nucleoid structure. Biochim Biophys Acta 1819:1–15. https://doi.org/10.1016/j.molbiol.2011.11.005
22. Bostjancic E, Zidar N, Stajner D, Glavac D (2010) MicroRNA outsourcing of RNA interference components to human mitochondria. PLoS ONE 6:e20220. https://doi.org/10.1371/journal.pone.0020220
23. Brown TA, Tkachuk AN, Shtengel G, Kopec BG, Bogenhagen DF, Hess HF, Clayton DA (2011) Superresolution fluorescence imaging of mitochondrial nucleoids reveals their spatial range, limits, and membrane interaction. Mol Cell Biol 31:4994–5010. https://doi.org/10.1128/MCB.05694-11
25. Burzio VA, Villota C, Villegas J, Landerer E, Boccardo E, Villa LL, Martínez R, López C, Gaete F, Toro V, Rodríguez X, Burzio LO (2009) Expression of a family of noncoding mitochondrial RNAs distinguishes normal from cancer cells. Proc Natl Acad Sci U S A 106:9430–9434. https://doi.org/10.1073/pnas.0903086106

26. Cai Z, Cao C, Ji L, Ye R, Wang D, Xia C, Wang S, Du Z, Hu N, Yu X (2020) RIC-seq for global in situ profiling of RNA–RNA spatial interactions. Nature 582:432–437

27. Calvo SE, Clauser KR, Mootha VK (2016) MitoCarta2.0: an updated inventory of mammalian mitochondrial proteins. Nucleic Acids Res 44:D1251–1257. https://doi.org/10.1093/nar/gkv1003

28. Camara Y, Asin-Cayuela J, Park CB, Metodiev MD, Shi Y, Ruzzenente B, Kukat C, Habermann B, Wihom R, Hultenby K, Franz T, Erdjument-Bromage H, Tempst P, Hallberg BM, Gustafsson CM, Larsson NG (2011) MTERF4 regulates translation by targeting the methyltransferase NSUN4 to the mammalian mitochondrial ribosome. Cell Metab 13:527–539. https://doi.org/10.1016/j.cmet.2011.04.002

29. Carossa V, Ghelli A, Tropeano CV, Valentino ML, Iommarini P, Carrozzo R, Murray J, Santorelli FM, Capaldi RA (2000) The T9176G mutation of human mtDNA gives a fully assembled but inactive ATP synthase when modeled in Escherichia coli. FEBS Lett 486:297–299. https://doi.org/10.1016/s0014-5793(00)02244-4

30. Cerritelli SM, Frolova EG, Feng C, Grinberg A, Love PE, Chen JY, Zhang X, Fu XD, Chen L (2019) R-ChIP for genome-wide mapping of R-loops by using catalytically inactive RNAseH1. Nat Protoc 14:1661–1685. https://doi.org/10.1038/s41596-019-0154-6

31. Chatterjee A, Seyfferth J, Lucci J, Gilsbach R, Preissl S, Botasso CM, Larsson NG (2011) MTERF4 regulates translation by targeting the methyltransferase NSUN4 to the mammalian mitochondrial ribosome. Cell Metab 13:527–539. https://doi.org/10.1016/j.cmet.2011.04.002

32. Cho SW, Park JS, Heo HJ, Park SW, Song S, Kim I, Han YM, Yamashita JK, Youm JB, Han J, Koh GY (2014) Dual modulation of the mitochondrial permeability transition pore and redox signaling synergistically promotes cardiomyocyte differentiation from pluripotent stem cells. J Am Heart Assoc 3:e000693. https://doi.org/10.1161/JAHA.113.00693

33. Chubunova A, Loseva E, Mazin P, Mitina A, Navalayeva T, Bilan D, Vishnyakova P, Marey M, Golovina A, Serebyakova M, Pietnev P, Rubtsova M, Mair W, Vanyushkina A, Khaitovich P, Belousov V, Vysokikh M, Sergiev P, Dontsova O (2019) LINC00116 codes for a mitochondrial peptide linking respiration and lipid metabolism. Proc Natl Acad Sci U S A 116:4940–4945. https://doi.org/10.1073/pnas.1809105116

34. Chun J, Faustino RS, Perez-Terzic C, Behfar A, Terzic A (2007) Mitochondrial oxidative metabolism is required for the cardiac differentiation of stem cells. Nat Clin Pract Cardiovasc Med 4(Suppl 1):S60-67. https://doi.org/10.1038/ncpcardio.0766

35. D’Lima NG, Ma J, Winkler L, Chu Q, Loh KH, Corpuz EO, Budnik BA, Lykke-Andersen J, Saghatelian A, Slavoff SA (2017) A human microprotein that interacts with the mRNA decapping complex. Nat Chem Biol 13:174–180. https://doi.org/10.1038/nchembio.2249

36. Dabkowski ER, Baseler WA, Williamson CL, Powell M, Razumugwa TT, Frisbee JC, Hollander JM (2010) Mitochondrial dysfunction in the type 2 diabetic heart is associated with alterations in spatially distinct mitochondrial proteomes. Am J Physiol Heart Circ Physiol 299:H529-540. https://doi.org/10.1152/ajpheart.00267.2010

37. David H, Bozner A, Meyer R, Wassilew G (1981) Pre- and postnatal development and ageing of the heart. Ultrastructural results. Exp Pathol Suppl 7:1–176

38. Dahan R, Takahashi M, Sharma S (2018) Cytosolic sensing of immuno-stimulatory DNA, the enemy within. Curr Opin Immunol 50:82–87. https://doi.org/10.1016/j.coi.2017.11.004

39. Dietrich A, Wallet C, Iqbal RK, Gualberto JM, Lotfi F (2015) Nuclear miRNA regulates the mitochondrial genome and quantitative data. Exp Pathol Suppl 7:1–176

40. Dorn GW 2nd (2015) Mitochondrial dynamism and heart disease: changing shape and shaping change. EMBO Mol Med 7:865–877. https://doi.org/10.15252/emmm.201404575

41. Dowen JM, Fan ZP, Hnisz D, Ren G, Abraham BJ, Zhang LN, Weintraub AS, Schujiers J, Lee TI, Zhao K, Young RA (2014) Control of cell identity genes occurs in insulated neighborhoods. Biochimie 117:48–62. https://doi.org/10.1016/j.biochi.2015.06.027

42. Distelmaier F, Haack TB, Catarino CB, Gallenmuller C, Rodenburg RJ, Strom TM, Baertling F, Meitinger T, Mayatepek E, Prokisch H, Klopstock T (2015) MRPL44 mutations cause a slowly progressive multisystem disease with childhood-onset hypertrophic cardiomyopathy. Neurogenetics 16:319–323. https://doi.org/10.1007/s11041-015-9444-2

43. Dorn GW 2nd (2015) Mitochondrial dysfunction and heart disease: changing shape and shaping change. EMBO Mol Med 7:865–877. https://doi.org/10.15252/emmm.201404575

44. Dowen JM, Fan ZP, Hnisz D, Ren G, Abraham BJ, Zhang LN, Weintraub AS, Schujiers J, Lee TI, Zhao K, Young RA (2014) Control of cell identity genes occurs in insulated neighborhoods in mammalian chromosomes. Cell 159:374–387. https://doi.org/10.1016/j.cell.2014.09.030

45. Dudek J, Maack C (2017) Barth syndrome cardiomyopathy. Cardiovasc Res 113:399–410. https://doi.org/10.1093/cvr/cvx014
52. El-Hattab AW, Scaglia F (2016) Mitochondrial cardiomyopathies. Front Cardiovasc Med 3:25. https://doi.org/10.3389/fcvm.2016.00025
53. Ekstrand MI, Falkenberg M, Rantanen A, Park CB, Gaspari M, Hultenby K, Rustin P, Gustafsson CM, Larsson NG (2004) Mitochondrial transcription factor A regulates mtDNA copy number in mammals. Hum Mol Genet 13:935–944. https://doi.org/10.1093/hmg/ddh109
54. Emperador S, Bayona-Bafaluy MP, Fernandez-Marmiesse A, Pineda M, Felgueroso B, Lopez-Gallardo E, Artuch R, Roca I, Ruiz-Pesini E, Couce ML, Montoya J (2016) Molecular-genetic characterization and rescue of a TSFM mutation causing childhood-onset ataxia and nonobstructive cardiomyopathy. Eur J Hum Genet 25:153–156. https://doi.org/10.1038/ejhg.2016.124
55. Falabella M, Kolesar JE, Wallace C, de Jesus D, Sun L, Tagu-Lo, Burzio VA (2019) Mitochondrial ncRNA targeting induces chemoresistance by reprogramming metabolism and regulating mitochondrial transcription. Cancer Res 79:1099–1038. https://doi.org/10.1158/1078-0432.CCR-18-2133
56. Falkenberg M (2018) Mitochondrial DNA replication in mammalian cells: overview of the pathway. Essays Biochem 62:287–296. https://doi.org/10.1042/EBC20170100
57. Fan F, Sun A, Zhao H, Liu X, Zhang W, Jin X, Wang C, Ma X, Shen C, Zou Y, Hu K, Ge J (2013) MicroRNA-34a promotes cardiomyocyte apoptosis post myocardial infarction through down-regulating aldehyde dehydrogenase 2. Curr Pharm Des 19:4865–4873. https://doi.org/10.2174/13816128113119900325
58. Fan S, Tian T, Chen W, Lv X, Lei X, Zhang H, Sun S,cai L, Pan G, He L, Ou Z, Lin X, Wang X, Perez MF, Tu Z, Ferrone S, Tannous BA, Li J (2019) Mitochondrial miRNA determines chemoresistance by reprogramming metabolism and regulating mitochondrial transcription. Cancer Res 79:1069–1084. https://doi.org/10.1158/0008-5472.CAN-18-2505
59. Fang R, Yu M, Li G, Chee S, Liu T, Schmitt AD, Ren B (2016) Mapping of long-range chromatix interactions by proximity ligation-assisted ChIP-seq. Cell Res 26:1345–1348. https://doi.org/10.1038/cr.2016.137
60. Farge G, Mehmedovc M, Baclayon M, van den Wildenberg SM, Roos WH, Gustafsson CM, Wuille GF, Falkenberg M (2014) In vitro-reconstituted nucleoids can block mitochondrial DNA replication and transcription. Cell Rep 8:66–74. https://doi.org/10.1016/j.celrep.2014.05.046
61. Feric M, Demarest TG, Tian J, Croteau DL, Bohr VA, Misteli T (2019) Self-assembly of multi-component mitochondrial nucleoids via phase separation. bioRxiv: 822858. https://doi.org/10.1101/822858
62. Fitzpatrick C, Bendek MF, Briones M, Farfan N, Silva VA, Nardocci G, Montecino M, Boland A, Deleuze JF, Villegas J, Villota C, Silva V, Lobos-Gonzalez L, Borgna V, Barrey E, Burzio LO, Burzio VA (2019) Mitochondrial ncRNA targeting induces cell cycle arrest and tumor growth inhibition of MDA-MB-231 breast cancer cells through reduction of key cell cycle progression factors. Cell Death Dis 10:423. https://doi.org/10.1038/s41419-019-1649-3
63. Fuadlenberg G, Abdennur N, Imakaev M, Goloborodko A, Mirny LA (2017) Emerging evidence of chromosome folding by loop extrusion. Cold Spring Harb Symp Quant Biol 82:45–55. https://doi.org/10.1101/cshsb.2017.82.034710
64. Fujino T, Ide T, Yoshida M, Onitsuka K, Tanaka A, Hata Y, Nishida M, Takehara T, Kanemaru T, Kitajima N, Takazaki S, Kurose H, Kang D, Sunagawa K (2012) Recombinant mitochondrial transcription factor A protein inhibits nuclear factor of activated T cells signaling and attenuates pathological hypertrophy of cardiac myocytes. Mitochondrion 12:449–458. https://doi.org/10.1016/j.mito.2012.06.002
65. Galimiche L, Serre V, Beinat M, Assouline Z, Lebre AS, Chretien D, Nietschke P, Benes V, Boddaert N, Sidi D, Brunelle F, Rio M, Munnich A, Rotig A (2011) Exome sequencing identifies MRPL3 mutation in mitochondrial cardiomyopathy. Hum Mutat 32:1225–1231. https://doi.org/10.1002/humu.21562
66. Gao S, Tian X, Chang H, Sun Y, Wu Z, Cheng Z, Dong P, Zhao Q, Ruan J, Bu W (2018) Two novel lncRNAs discovered in human mitochondrial DNA using PacBio full-length transcription data. Mitochondrial 38:41–47. https://doi.org/10.1016/j.mito.2017.08.002
67. Garnier A, Fortin D, Delomenie C, Momken I, Vekslers V, Ventura-Clapier R (2003) Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles. J Physiol 551:491–501. https://doi.org/10.1113/jphysiol.2003.045104
68. Garrido N, Gripparic L, Jokitalo E, Wartiovaara J, van der Bie AM, Spellbrink JN (2003) Composition and dynamics of human mitochondrial nucleoids. Mol Biol Cell 14:1583–1596. https://doi.org/10.1091/mbc.e02-07-0399
69. Gaspar JA, Doss MX, Hengstler JG, Cadenas C, Hescheler J, Sachindis A (2014) Unique metabolic features of stem cells, cardiomyocytes, and their progenitors. Circ Res 114:1346–1360. https://doi.org/10.1161/CIRCRESAHA.113.302021
70. Ge Y, Shi X, Boopathy S, McDonald J, Smith AW, Chao LH (2020) Two forms of Opal1 cooperate to complete fusion of the mitochondrial inner-membrane. Elife 9:e50973. https://doi.org/10.7554/eLife.50973
71. Gerhold JM, Cansiz-Arda S, Lohmus M, Engberg O, Reyes A, van Rennes H, Sanz A, Holt JI, Cooper HM, Spellbrink JN (2015) Human mitochondrial DNA-protein complexes attach to a cholesterol-rich membrane structure. Sci Rep 5:15292. https://doi.org/10.1038/srep15292
72. Ghosh-Choudhary S, Liu J, Finkel T (2020) Metabolic regulation of cell fate and function. Trends Cell Biol 30:201–212. https://doi.org/10.1016/j.tcb.2019.12.005
73. Ginno PA, Lott PL, Christensen HC, Korf I, Chedin F (2012) L-loop formation is a distinctive characteristic of unmethylated human CpG island promoters. Mol Cell 45:814–825. https://doi.org/10.1016/j.molcel.2012.01.017
74. Giordano C, Perli E, Orlandi M, Pisanu A, Tippen HA, He L, Ierino R, Petruzziello L, Terzi A, Autore C, Petrozza V, Gallo P, Taylor RW, d’Amati G (2013) Cardiomyopathies due to homoplastic mitochondrial tRNA mutations: morphologic and molecular features. Hum Pathol 44:1262–1270. https://doi.org/10.1016/j.humpath.2012.10.011
75. Goffart S, von Kleist-Retzow JC, Wiesner RJ (2004) Regulation of mitochondrial proliferation in the heart: power-plant failure contributes to cardiac failure in hypertrophy. Cardiovasc Res 64:198–207. https://doi.org/10.1016/j.cardiores.2004.06.030
76. Goldstein JD, Shanske S, Bruno C, Perszyk AA (1999) Maternally inherited mitochondrial cardiomyopathy associated with a C-to-T transition at nucleotide 3303 of mitochondrial DNA in the tRNA(Leu(UUR)) gene. Pediatr Dev Pathol 2:78–85. https://doi.org/10.1016/s1043-984x(99)00094
77. Gong T, Liu L, Jiang W, Zhou R (2020) DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol 20:95–112. https://doi.org/10.1038/s41577-019-0215-7
78. Gong Z, Tan E, Muzumdar R (2014) Humanin and age-related diseases: a new link? Front Endocrinol (Lausanne) 5:210. https://doi.org/10.3389/fendo.2014.00210
79. Gorman GS, Chinnery PF, DiMauro S, Hirano M, Koga Y, McFarland R, Suomalainen A, Thorburn DR, Zeviani M, Turnbull DM (2016) Mitochondrial diseases. Nat Rev Dis Primers 2:16080. https://doi.org/10.1038/nrdp.2016.80
80. Graf M, Bonetti D, Lockhart A, Serhal K, Kellner V, Maicher A, Jolivet P, Teixeira MT, Luke B (2017) Telomere length determines TERRA and R-Loop regulation through the cell cycle. Cell 170(72–85):e14. https://doi.org/10.1016/j.cell.2017.06.006
81. Groh M, Gromak N (2014) Out of balance: R-loops in human disease. PLoS Genet 10:e1004630. https://doi.org/10.1371/journal.pgen.1004630
82. Guan X, Wang L, Liu Z, Guo X, Jiang Y, Lu Y, Peng Y, Liu T, Yang B, Shan H, Zhang Y, Xu C (2016) miR-101a promotes cardiac hypertrophy by targeting mitofusin 2. J Mol Cell Cardiol 99:207–217. https://doi.org/10.1016/j.yjcc.2016.08.016
83. Guo A, Wang Y, Chen B, Wang Y, Yuan J, Zhang L, Hall D, Wu J, Shi Y, Zhu Q, Chen C, Thiel WH, Zhan X, Weiss RM, Zhan F, Musselman CA, Puffall M, Zhu W, Au KP, Hong J, Anderson ME, Gruter CE, Song LS (2018) E-C coupling structural protein juncophilin-2 encodes a stress-adaptive transcription regulator. Science 362:aan3303. https://doi.org/10.1126/science.aan3303
84. Gusic M, Prokisch H (2020) ncRNAs: new players in mitochondrial disease and health disease? Front Genet 11:95. https://doi.org/10.3389/fgene.2020.00095
85. Hao Z, Wu T, Cui X, Zhu P, Tan C, Dou X, Hsu KW, Lin YT, Peng PH, Zhang LS, Gao Y, Hu L, Sun HL, Zhu A, Liu J, Wu KJ, He C (2020) N(6)-deoxyadenosine methylation in mammalian mitochondrial DNA. Mol Cell 78(383–395):e388. https://doi.org/10.1016/j.molcel.2020.02.018
86. Hashimoto Y, Niikura T, Tajima H, Yasukawa T, Sudo H, Ito Y, Sato M, Makino S, Oikawa S, Fukuda K (2010) Overexpression of TFAM or twinkle increases mtDNA copy number and facilitates cardioprotection associated with limited mitochondrial oxidative stress. PLoS ONE 10:e0119687. https://doi.org/10.1371/journal.pone.0119687
87. Hatano A, Okada J, Washio T, Hisada T, Sugiuira S (2015) Distinct functional roles of cardiac mitochondrial subpopulations revealed by a 3D simulation model. Biophys J 108:2732–2739. https://doi.org/10.1016/j.bpj.2015.04.031
88. Hattori F, Chen H, Yamashita H, Tohyama S, Satoh YS, Yuasa S, Ikeda M, Ide T, Tsutsui H, Hayashidani S, Kang D, Suetsugu N, Nakamura K, Utsumi H, Hamasaki N, Takeshita A (2001) Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res 88:529–535. https://doi.org/10.1161/01.res.88.5.529
89. Ikeda M, Ide T, Fujino T, Arai S, Sakai K, Kakino T, Tynningmaa H, Yamasaki T, Yamada K, Kang D, Suomalainen A, Sunagawa K (2015) Overexpression of TFAM or twinkle increases mtDNA copy number and facilitates cardioprotection associated with limited mitochondrial oxidative stress. PLoS ONE 10:e0119687. https://doi.org/10.1371/journal.pone.0119687
90. Ikeuchi M, Matsusaka H, Kang D, Matsushima S, Ide T, Kubota T, Fujikawa T, Hamasaki N, Takeshita A, Sunagawa K, Tsutsui H (2005) Overexpression of mitochondrial transcription factor a ameliorates mitochondrial deficiencies and cardiac failure after myocardial infarction. Circulation 112:683–690. https://doi.org/10.1161/CIRCULATIONAHA.104.524835
91. Inagaki H, Kitano S, Lin KH, Maeda S, Saito T (1998) Inhibition of mitochondrial gene expression by antisense RNA of mitochondrial transcription factor A (mtTFA). Biochem Mol Biol Int 45:567–573. https://doi.org/10.1080/1521654980202962
92. Ingraham CA, Burwell LS, Skalska J, Brookes PS, Howell RL, Cao D, Ainsworth TA, Paulsson J (2016) Accurate concentration control of mitochondrial oxidative communication and T Cell fate. Cell 171(103–119):e118. https://doi.org/10.1016/j.cell.2017.09.001
93. Isoda T, Moore AJ, Graber JJ, Agaronyan K, Morozov YI, Graber JJ, Murre C (2017) Non-coding transcription instructs chromatin folding and compartmentalization to dictate enhancer-promoter communication and T Cell fate. Cell 171(103–119):e118. https://doi.org/10.1016/j.cell.2017.09.001
94. Iwamoto T, Ishiyama E, Ishida K, Yamashita T, Tomita H, Ozaki M, Tone T, Kagami T, Nakamura T, Muto T, Sato M, Makino S, Oikawa S, Fukuda K (2010) Overexpression of TFAM or twinkle increases mtDNA copy number and facilitates cardioprotection associated with limited mitochondrial oxidative stress. PLoS ONE 10:e0119687. https://doi.org/10.1371/journal.pone.0119687
95. Jajoo R, Jung Y, Huh D, Viana MP, Rafeelski SM, Springer M, Paulsson J (2016) Accurate concentration control of mitochondrial and nuclear DNA. Science 351:169–172. https://doi.org/10.1126/science.aaa8714
109. Jaquenod De Giusti C, Roman B, Das S (2018) The influence of MicroRNAs on mitochondrial calcium. Front Physiol 9:1291. https://doi.org/10.3389/fphys.2018.01291

110. Jecck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, Marzluff WF, Sharpless NE (2013) Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA 19:141–157. https://doi.org/10.1017/rna.2013.70

111. Kakihana Y, Ito T, Nakahara M, Yamaguchi K, Yasuda T (2016) Sepsis-induced myocardial dysfunction: pathophysiology and management. J Intensive Care 4:22. https://doi.org/10.1186/s40560-016-0148-1

112. Kasahara A, Cipolat S, Chen Y, Dorn GW 2nd, Scorrano L (2013) Mitochondrial fusion directs cardiomyocyte differentiation via calcineurin and Notch signaling. Science 342:734–737. https://doi.org/10.1126/science.1241359

113. Kasashima K, Sumitani M, Endo H (2011) Human mitochondrial transcription factor A is required for the segregation of mitochondrial DNA in cultured cells. Exp Cell Res 317:210–220. https://doi.org/10.1016/j.yexcr.2010.10.008

114. Kato T (2008) Role of mitochondrial DNA in calcium signaling abnormality in bipolar disorder. Cell Calcium 44:92–102. https://doi.org/10.1016/j.ceca.2007.11.005

115. Kauffman P, Neto JM, Camargo EE, Carvalho N, Muraco B, Leao LE, Costa ER (2015) Dynamic evaluation of muscular circulation. I. A comparative study between local clearance of 131-I-Hippuran and 24-Na. Rev Hosp Clin Fac Med Sao Paulo 30:362–365

116. Kaufman BA, Durisic N, Matvevskyi JM, Costantino S, Hancock MA, Grutter P, Shroutbidge EA (2007) The mitochondrial transcription factor TFAM coordinates the assembly of multiple DNA molecules into nucleoid-like structures. Mol Biol Cell 18:3225–3236. https://doi.org/10.1091/mbc.e07-05-0404

117. Kim JJ, Lee SY, Miller KM (2019) Preserving genome integrity and function: the DNA damage response and histone modifications. Crit Rev Biochem Mol Biol 54:208–241. https://doi.org/10.1080/10409238.2019.1620676

118. Kim KH, Son JM, Benayoun BA, Lee C (2018) The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab 28(516–524):e517. https://doi.org/10.1016/j.cmet.2018.06.008

119. Kim Y, Shi Z, Zhang H, Finkelstein BI, Yu H (2019) Human cohesion complexes DNA by loop extrusion. Science 366:1345–1349. https://doi.org/10.1126/science.aaz4475

120. King GA, Hashemi Shabestari M, Taris KH, Pandey AK, Venkatesh S, Thilagavathi J, Singh K, Krishna Kopisetty R, Temiazov D, Roos WH, Suzuki CK, Wuite GJL (2018) Acetylation of dehydrogenase 2 (ALDH2) in Mus musculus cardiac myocytes. Eur Rev Med Pharmacol Sci 22:752–758. https://doi.org/10.1177/1178222X1800004002

121. Kotantis S, Silva LM, Irmscher S, Jones RM, Folkers L, Gromak N, Petermann E (2016) Increased global transcription activity during cardiomyopathy in patient iPSC-derived cardiomyocytes with MT-RNR2 mutation. Stem Cell Rep 10:808–821. https://doi.org/10.1016/j.stemcr.2018.01.013

122. Kukat C, Davies KM, Wurm CA, Bonekamp NA, Kuhl I, Joos F, Polosa PL, Park CB, Posse V, Falkenberg M, Jakobs S, Kuhlbrandt W, Larsson NG (2015) Cross-strand binding of TFAM to a single mtDNA molecule, associated with the mitochondrial nucleoid. Proc Natl Acad Sci U S A 112:11288–11293. https://doi.org/10.1073/pnas.1512131112

123. Kumarswamy R, Bauters C, Volkman I, Maury F, Fetisch J, Holzmann A, Lemesle G, de Groote P, Pinet F, Thum T (2014) Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure. Circ Res 114:1569–1575. https://doi.org/10.1161/CIRCRESAHA.114.303915

124. Kummer E, Ban N (2021) Mechanisms and regulation of protein synthesis in mitochondria. Nat Rev Mol Cell Biol. https://doi.org/10.1038/s41580-021-00332-2

125. Kunkel GH, Chaturvedi P, Villota C, Lopez C, Restovic F, Martinez R, Castillo O, Burzio LO (2011) Nuclear localization of the mitochondrial ncRNAs in normal and cancer cells. Cell Oncol (Dordr) 34:297–305. https://doi.org/10.1007/s13402-011-0018-8

126. Larsson NG, Wang J, Wilhelmssson H, Oldfors A, Rustin P, Lewandoski M, Barsh GS, Clayton DA (1998) Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice. Nat Genet 18:231–236. https://doi.org/10.1038/ng0398-231

127. Larnder E, Villegas J, Burzio VA, Oliveira L, Villota C, Lopez C, Restovic F, Martinez R, Castillo O, Burzio LO (2011) Nuclear localization of the mitochondrial ncRNAs in normal and cancer cells. Cell Oncol (Dordr) 34:297–305. https://doi.org/10.1007/s13402-011-0018-8

128. Lederer E, Jaquenod De Giusti C, Roman B, Tyagi SC (2018) Mechanisms of TFAM-mediated cardiomyocyte protection. Can J Physiol Pharmacol 96:173–181. https://doi.org/10.1139/cjpp-2016-0718

129. Lee SR, Han J (2017) Mitochondrial nucleoid: shield and barrier of mitochondrial DNA molecules into nucleoid-like structures. Mol Biol Cell 18:3225–3236. https://doi.org/10.1091/mbc.e07-05-0404

130. Lee SR, Han J (2017) Mitochondrial nucleoid: shield and barrier of mitochondrial DNA molecules into nucleoid-like structures. Mol Biol Cell 18:3225–3236. https://doi.org/10.1091/mbc.e07-05-0404

131. Lebrecht D, Setzer B, Ketelsen UP, Haberstroh J, Walker UA (2003) Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation 108:2423–2429. https://doi.org/10.1161/01.HER.0000093196.59829.DF

132. Lee C, Yen K, Cohen P (2013) Humanin: a harbinger of mitochondrial-derived peptides? Trends Endocrinol Metab 24:222–228. https://doi.org/10.1016/j.tem.2013.01.005

133. Lee SR, Han J (2017) Mitochondrial nucleoid: shield and barrier of mitochondrial DNA molecules into nucleoid-like structures. Mol Biol Cell 18:3225–3236. https://doi.org/10.1091/mbc.e07-05-0404

134. Li H, Wang J, Wilhelmssson H, Hansson A, Thoren P, Duffly J, Rustin P, Larsson NG (2000) Genetic modification of survival in tissue-specific knockout mice with mitochondrial cardiomyopathy. Proc Natl Acad Sci U S A 97:3467–3472. https://doi.org/10.1073/pnas.97.7.3467

135. Li S, Pan H, Tan C, Sun Y, Song Y, Zhang X, Yang W, Wang X, Li D, Bai Y, Ma Q, Xu C, Zhuo X, Kang L, Fu Y, Xu X, Xu J, Zhou N, Han F, Qin D, Huang W, Liu Z, Yan Q (2018) Mitochondrial dysfunction contribute to hypertrophic cardiomyopathy in patient iPSC-derived cardiomyocytes with MT-RNR2 mutation. Stem Cell Rep 10:808–821. https://doi.org/10.1016/j.stemcr.2018.01.013

136. Li SP, Liu B, Song B, Wang CX, Zhou YC (2015) miR-28 promotes cardiac ischemia by targeting mitochondrial aldehyde dehydrogenase 2 (ALDH2) in mus musculus cardiac myocytes. Eur Rev Med Pharmacol Sci 19:752–758. https://doi.org/10.2147/erms.s60949

137. Li X, Zhou B, Chen L, Gou LT, Li H, Fu XD (2017) GRID-seq identifies cardiac ischemia signatures across cardiomyocytes and fibroblasts. Circulation 135:1192–1199. https://doi.org/10.1161/CIRCULATIONAHA.115.023743

138. Lieberman-Aiden E, van Berkum NL, Williams L, Imaekawa M, Ragoczy T, Telling A, Amit I, Lajoie BR, Sabo PJ, Dorschner MO, Sandstrom R, Bernstein B, Bender MA, Groudine M, Girkar A, Stamatoyannopoulos J, Mirny LA, Lander ES, Dekker J (2009) Comprehensive mapping of long-range interactions
reveals folding principles of the human genome. Science 326:289–293. https://doi.org/10.1126/science.1181369

139. Lin B, Feng DG, Xu J (2019) microRNA-665 silencing improves cardiac function in rats with heart failure through activation of the cAMP signaling pathway. J Cell Physiol 234:13169–13181. https://doi.org/10.1002/jcp.27987

140. Lin YF, Xiao MH, Chen HX, Meng Y, Zhao N, Yang L, Tang H, Wang JL, Liu X, Zhu Y, Zhuang SM (2019) A novel mitochondrial micropeptide MPM enhances mitochondrial respiratory activity and promotes myogenic differentiation. Cell Death Dis 10:528. https://doi.org/10.1038/s41419-019-1767-y

141. Lindahl T (1993) Instability and decay of the primary structure of DNA. Nature 362:709–715. https://doi.org/10.1038/362709a0

142. Liu BL, Cheng M, Hu S, Wang S, Wang L, Tu X, Huang CX, Jiang H, Wu G (2018) Overexpression of miR-142-3p improves mitochondrial function in cardiac hypertrophy. Biomed Pharmacother 108:1347–1356. https://doi.org/10.1016/j.biopha.2018.09.146

143. Liu X, Lai W, Li Y, Chen S, Liu B, Zhang N, Mo J, Lu C, Zheng J, Du YR, Jiang G, Xu GL, Wang H (2020) N6-methyladenine is incorporated into mammalian genome by DNA polymerase. Cell Res. https://doi.org/10.1038/s41422-020-0317-6

144. Liu X, Wang X, Li J, Hu S, Deng Y, Yin H, Bao X, Zhang QC, Wang G, Wang B, Shi Q, Shan G (2020) Identification of meciRNAs and their roles in the mitochondrial entry of proteins. Sci China Life Sci 63:1429–1449. https://doi.org/10.1007/s11427-020-1631-9

145. Liu Z, Song Y, Li D, He X, Li S, Wu B, Wang W, Gu S, Zhu X, Wang X, Zhou Q, Dai Y, Yan Q (2014) The novel mitochondrial 16S rRNA 2336T>C mutation is associated with hypertrophic cardiomyopathy. J Med Genet 51:176–184. https://doi.org/10.1136/jmedgenet-2013-101818

146. Lopaschuk GD, Jaswal JS (2010) Energy metabolic phenotype of the cardiomyocyte during development, differentiation, and postnatal maturation. J Cardiovasc Pharmacol 56:130–140. https://doi.org/10.1177/0022049510362063

147. Lopaschuk GD, Spafford MA, Marsh DR (1991) Glycolysis is predominant source of myocardial ATP production immediately after birth. Am J Physiol 261:H1698-1705. https://doi.org/10.1152/ajpheart.1991.261.6.H1698

148. Luevano-Martinez LA, Forni MF, dos Santos VT, Souza-Pinto NC, Kowalowski AJ (2015) Cardiolipin is a key determinant for mtDNA stability and segregation during mitochondrial stress. Biochim Biophys Acta 1847:587–598. https://doi.org/10.1016/j.bbabiobio.2015.03.007

149. Luo S, Valencia CA, Zhang J, Lee NC, Slone J, Gui B, Wang X, Li Z, Dell S, Brown J, Chen SM, Chien YH, Hwu WL, Fan PC, Wong LJ, Atwal PS, Huang T (2018) Biparental inheritance of mitochondrial DNA in humans. Proc Natl Acad Sci U S A 115:13039–13044. https://doi.org/10.1073/pnas.1809461115

150. Macfarlane LA, Murphy PR (2010) MicroRNA: biogenesis, function and role in cancer.Curr Genomics 11:537–561. https://doi.org/10.2174/138920210793175895

151. Makarewicz CA, Baskin KK, Munir AZ, Bezprozvannaya S, Sharma G, Khemtong C, Shah AM, McAnally JR, Malley CR, Szveda LJ, Basset-Duby R, Olson EN (2018) MOXI Is a mitochondrial micropeptide that enhances fatty acid beta-oxidation. Cell Rep 23:3701–3709. https://doi.org/10.1016/j.celrep.2018.05.058

152. Mankar AN, Schmidt T, Chauhan D, Goldeck M, Honing K, Gaidt M, Kubarenko AV, Andreeva L, Hopfer KP, Hornung V (2014) Cytosolic RNA:DNA hybrids activate the cGAS-STING axis. EMBO J 33:2937–2946. https://doi.org/10.15252/embj.201488726

153. Marom S, Blumberg A, Kundaje A, Mishmar D (2019) mtDNA Chromatin-like organization is gradually established during Mammalian embryogenesis. iScience 12:141–151. https://doi.org/10.1016/j.isci.2018.12.032

154. Matlab MA, Roussin W, Kraft G, Berner P, Schwartz A (1978) On the existence of two populations of mitochondria in a single organ. Respiration, calcium transport and enzyme activities. Biochem Biophys Res Commun 84:482–488. https://doi.org/10.1016/0006-291x(78)90194-8

155. Matsumoto A, Pasut A, Matsumoto M, Yamashita R, Fung J, Monteleone E, Saghatelian A, Nakayama KI, Ciohessy JG, Pandoi PP (2017) mTORC1 and muscle regeneration are regulated by the LINCO0961-encoded SPAR polypeptide. Nature 541:228–232. https://doi.org/10.1038/nature21034

156. Matsushima Y, Goto Y, Kaguni LS (2010) Mitochondrial Lon protease regulates mitochondrial DNA copy number and transcription by selective degradation of mitochondrial transcription factor A (TFAM). Proc Natl Acad Sci U S A 107:18410–18415. https://doi.org/10.1073/pnas.1008924107

157. Mayr JA (2015) Lipid metabolism in mitochondrial membranes. J Inher Metab Dis 38:137–144. https://doi.org/10.1007/s10545-014-9748-x

158. Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer M, Loewer A, Ziebold U, Landthaler M, Kocks C, le Noble F, Rajewsky N (2013) Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 495:333–338. https://doi.org/10.1038/nature11928

159. Mercer TR, Neph S, Dinger ME, Crawford J, Smith MA, Shearwood AM, Haugen E, Bracken CP, Rackham O, Stamatoyanopoulos JA, Filipovska A, Mattick JS (2011) The human mitochondrial transcriptome. Cell 146:645–658. https://doi.org/10.1016/j.cell.2011.06.051

160. Mok BY, de Moraes MH, Zeng J, Bosch DE, Kotrys AV, Raguam R, Hsu F, Radye MC, Peterson SB, Mootha VK, Mougous JD, Liu DR (2020) A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. Nature 583:631–637. https://doi.org/10.1038/s41586-020-2477-4

161. Montoya J, Perez-Gallardo E, Herrero-Martín MD, Martinez-Romero I, Gomez-Duran A, Pachue D, Carreras M, Diez-Sanchez C, Perez-Perez MJ, Ruiz-Pesini E (2009) Diseases of the human mitochondrial oxidative phosphorylation system. Adv Exp Med Biol 652:47–67. https://doi.org/10.1007/978-90-481-2813-6_5

162. Muftuoglu M, Mori MP, de Souza-Pinto NC (2014) Formation and repair of oxidative damage in the mitochondrial DNA. Mitochondrion 17:164–181. https://doi.org/10.1016/j.mito.2014.03.007

163. Muller M, Ahumada-Castro U, Sanhueza M, Gonzalez-Billault C, Court FA, Cardenas C (2018) Mitochondria and Calcium regulation as basis of Neurodegeneration associated With aging. Front Neurosci 12:470. https://doi.org/10.3389/fnins.2018.00470

164. Mumbach MR, Granja JM, Flynn RA, Roake CM, Satpathy AT, Rubin AJ, Qi Y, Jiang Z, Shams S, Louie BH, Guo JK, Gennert DG, Corces MR, Khavari PA, Atianand MK, Artandi SE, Fitzgerald KA, Greenleaf WJ, Chang HY (2019) HiChiRP reveals RNA-associated chromosome conformation. Nat Methods 16:489–492. https://doi.org/10.1038/s41592-019-0407-x

165. Mumbach MR, Rubin AJ, Flynn RA, Dai C, Khavari PA, Greenleaf WJ, Chang HY (2016) HiChiP: efficient and sensitive analysis of protein-directed genome architecture. Nat Methods 13:919–922. https://doi.org/10.1038/nmeth.3999

166. Muzumdar RH, Huffman DM, Calvert JW, Jha S, Weinberg Y, Cui L, Nemkal A, Atzmon G, Klein L, Gundewar S, Ji SY, Lava M, Predmore BL, Lefer DJ (2010) Acute humanin therapy attenuates myocardial ischemia and reperfusion injury in mice.
Arterioscler Thromb Vasc Biol 30:1940–1948. https://doi.org/10.1161/ATVBAHA.110.205997

167. Naeem MM, Maheshan R, Costford SR, Wahedi A, Trajkovski M, Plavec J, Yatsunyak LA, Ciesielski GL, Kaufman BA, Jondi-heimer N (2019) G-quadruplex-mediated reduction of a patho- genic mitochondrial heteroplasmy. Hum Mol Genet 28:3163–3174. https://doi.org/10.1093/hmg/ddz153

168. Neary MT, Ng KE, Ludtmann MH, Hall AR, Piotrowska I, Ong SB, Hausenloy DJ, Mohan TJ, Abramov AV, Breckenridge RA (2014) Hypoxia signaling controls postnatal changes in cardiac mitochondrial morphology and function. J Mol Cell Cardiol 74:340–352. https://doi.org/10.1016/j.yjmcc.2014.06.013

169. Nego HB, Kaiser JT, Chan DC (2011) The mitochondrial tran- scription and packaging factor Tfam imposes a U-turn on mito- chondrial DNA. Nat Struct Mol Biol 18:1290–1296. https://doi. org/10.1038/nsmb.2159

170. Nego HB, Lovely GA, Phillips R, Chan DC (2014) Distinct structural features of TFAM drive mitochondrial DNA packaging versus transcriptional activation. Nat Commun 5:3077. https://doi.org/10.1038/ncomms4077

171. Oka T, Hikoso S, Yamaguchi O, Taneike M, Takeda T, Oka S, Murakawa T, Nishida K, Akira S, Yamamoto A, Komuro I, Otsu K (2012) Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 485:251–255. https://doi.org/10.1038/nature10992

172. Osman C, Haag M, Potting C, Rodenfels J, Dip PV, Wieland FT, Brugger B, Westermann B, Langer T (2009) The genetic interac- tome of prohibitins: coordinated control of cardiopin and phophatidylyethanolamine by conserved regulators in mitochon- dria. J Cell Biol 184:583–596. https://doi.org/10.1083/jcb.20081 0189

173. Osman C, Noriega TR, Okreglak V, Fung JC, Walter P (2015) Integrity of the yeast mitochondrial genome, but not its distribu- tion and inheritance, relies on mitochondrial fission and fusion. Proc Natl Acad Sci U S A 112:E947–956. https://doi.org/10.1073/ pnas.1410073112

174. Ou SM, Chu H, Chao PW, Lee YJ, Kuo SC, Chen TJ, Tseng CM, Shih CJ, Chen YT (2016) Long-term mortality and major adverse cardiovascular events in sepsis survivors. A nationwide population-based study. Am J Respir Crit Care Med 194:209–217. https://doi.org/10.1164/rcrm.2015-0230OC

175. Ozaki Y, Yamashita T, Ishiguro S (2009) Mitochondrial m-cal- pain plays a role in the release of truncated apoptosis-inducing factor from the mitochondria. Biochim Biophys Acta 1793:1848– 1859. https://doi.org/10.1016/j.bbamcr.2009.10.002

176. Palikaras K, Lionaki E, Tavernarakis N (2018) Mechanisms of mitophagy in cellular homeostasis, physiology and pathol- ogy. Nat Cell Biol 20:1013–1022. https://doi.org/10.1038/ s41556-018-0176-2

177. Phillips DD, Garboczi DN, Singh K, Hu Z, Leppla SH, Leyshat CE (2013) The sub-nanomolar binding of DNA-RNA hybrids by the single-chain Fv fragment of antibody S9.6. J Mol Recognit 26:376–381. https://doi.org/10.1002/jmr.2284

178. Pohjoismai J, Wanrooij S, Hyvarinen AK, Goffart S, Holt IJ, Speibrink JN, Jacobs HT (2006) Alterations to the expression level of mitochondrial transcription factor A, TFAM, modify the s41556-018-0176-2

179. Pontogna W, Chattipakorn SC, Chattipakorn N (2015) Chronic testosterone replacement exerts cardioprotection against cardiac ischemia-reperfusion injury by attenuating mitochondrial dys- function in testosterone-deprived rats. PLoS ONE 10:e0122503. https://doi.org/10.1371/journal.pone.0122503

180. Porter GA Jr, Hom J, Hoffman D, Quintanilla R, de Mesy BK, Sheu SS (2011) Bioenergetics, mitochondria, and cardiac myo- cyte differentiation. Prog Pediatr Cardiol 31:75–81. https://doi. org/10.1016/j.ppedcard.2011.02.002

181. Qin Q, Mehta H, Yen K, Navarrete G, Brandhorst S, Wan J, Delrio S, Zhang X, Lerman LO, Cohen P, Lerman A (2018) Chronic treatment with the mitochondrial peptide humanin prevents age-related myocardial fibrosis in mice. Am J Physiol Heart Circ Physiol 315:H1127–H1136. https://doi.org/10.1152/ajpheart.00685.2017

182. Rackham O, Shearwood AM, Mercer TR, Davies SM, Mattick JS, Filipovska A (2011) Long noncoding RNAs are generated from the mitochondrial genome and regulated by nuclear- encoded proteins. RNA 17:2085–2093. https://doi.org/10.1261/ rna.029405.111

183. Ries R, Zaccara S, Klein P, Olarerin-George A, Namkoong S, Pickering BP, Patil DP, Kwak H, Lee JH, Jaffrey SR (2019) m(6)A enhances the phase separation potential of mRNA. Nature 571:424–428. https://doi.org/10.1038/s41586-019-1374-1

184. Richter C, Park JW, Ames BN (1988) Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc Natl Acad Sci U S A 85:6465–6467. https://doi.org/10.1073/pnas.85.17. 6465

185. Rozanov RJ, Zaccara S, Klein P, Olarerin-George A, Namkoong S, Pickering BP, Patil DP, Kwak H, Lee JH, Jaffrey SR (2019) m(6)A enhances the phase separation potential of mRNA. Nature 571:424–428. https://doi.org/10.1038/s41586-019-1374-1

186. Ries R, Zaccara S, Klein P, Olarerin-George A, Namkoong S, Pickering BP, Patil DP, Kwak H, Lee JH, Jaffrey SR (2019) m(6)A enhances the phase separation potential of mRNA. Nature 571:424–428. https://doi.org/10.1038/s41586-019-1374-1

187. Rockwell S, Irvin CG, Kelley M (1988) Preclinical studies of a perfluorochemical emulsion as an adjunct to radiotherapy. Int J Radiat Oncol Biol Phys 15:913–920. https://doi.org/10.1016/0360- 3016(88)90126-5

188. Rosa-Garrido M, Chapski DJ, Schmitt AD, Kimball TH, Karrassi E, Monte E, Balderas E, Pellegrini M, Shih TT, Soehalim E, Liem D, Fung P, Galjart NJ, Ren S, Wang Y, Ren B, Vondriska TM (2017) High-resolution mapping of chromatin conformation in cardiac myocytes reveals structural remodeling of the epigenome in heart failure. Circulation 136:1613–1625. https://doi. org/10.1161/CIRCULATIONAHA.117.029430

189. Sabari BR, Dall’Agnese A, Boija A, Klein IA, Coffey EL, Shrini- varas K, Abraham BJ, Hannett NM, Zamudio AV, Manteiga JC, Li CH, Guo YE, Day DS, Schuierers J, Vaseile E, Malik S, Hnisz D, Lee TI, Cisse II, Roeder RG, Sharp PA, Chakraborty AK, Young RA (2018) Coactivator condensation at super-enhancers links phase separation and gene control. Science 361:eaar3958. https://doi.org/10.1126/science.aar3958

190. Saldana-Meyer R, Rodriguez-Hernaiz J, Escobar T, Nishina M, Jacome-Lopez K, Nara EP, Bruneau BG, Tsirigos A, Furlan- Magaril M, Skok J, Reinberg D (2019) RNA interactions are essential for CTCF-mediated genome organization. Mol Cell 76:412–422(e415. https://doi.org/10.1016/j.molcel.2019.08.015

191. Salzmann J, Chen RE, Olsen MN, Wang PL, Brown PO (2013) Cell-type specific features of circular RNA expression. PLoS Genet 9:e1003777. https://doi.org/10.1371/journal.pgen.10037 77

192. Santorelli FM, Tani J, Manta P, Casali C, Krishna S, Hays AP, Mancini DM, DiMauro S, Hirano M (1999) Maternally inheri- ted cardiomyopathy: an atypical presentation of the mtDNA 12S
rRNA gene A1555G mutation. Am J Hum Genet 64:295–300. https://doi.org/10.1086/302188

193. Schaper J, Meiser E, Stammer G (1985) Ultrastructural morphometric analysis of myocardium from dogs, rats, hamsters, mice, and from human hearts. Circ Res 56:377–391. https://doi.org/10.1161/01.res.56.3.377

194. Schwarzer M, Schrepper A, Amorim PA, Osterholt M, Doenst T (2013) Pressure overload differentially affects respiratory capacity in interstitial and subsarcomelial mitochondria. Am J Physiol Heart Circ Physiol 304:H529–537. https://doi.org/10.1152/heartphysiol.00699.2012

195. She H, Yang Q, Sheppard K, Smith Y, Miller G, Testa C, Mao Z (2011) Direct regulation of complex I by mitochondrial MEF2D is disrupted in a mouse model of Parkinson disease and in human patients. J Clin Invest 121:930–940. https://doi.org/10.1172/JCI43871

196. Shi Y, Dierckx A, Wanrooij PH, Wanrooij S, Larsson NG, Wilmelsson LM, Falkenberg M, Gustafsson CM (2012) Mammalian transcription factor A is a core component of the mitochondrial transcription machinery. Proc Natl Acad Sci U S A 109:16510–16515. https://doi.org/10.1073/pnas.1119738109

197. Shintani-Ishida K, Yoshida K (2015) Mitochondrial m-calpain opens the mitochondrial permeability transition pore in ischemia-reperfusion. Int J Cardiol 197:26–32. https://doi.org/10.1016/j.ijcard.2015.06.010

198. Sigova AA, Abraham BJ, Ji X, Molinie B, Hannett NM, Guo YE, Jiang M, Giallourakis CC, Sharp PA, Young RA (2015)Transcription factor trapping by RNA in gene regulatory elements. Science 350:978–981. https://doi.org/10.1126/science.aad3346

199. Silva S, Camino LP, Aguilera A (2018) Human mitochondrial degradosome prevents harmful mitochondrial R loops and mitochondrial genome instability. Proc Natl Acad Sci U S A 115:11024–11029. https://doi.org/10.1073/pnas.1807258115

200. Skene PJ, Henikoff S (2017) An efficient targeted nuclease strategy for high-resolution mapping of DNA binding sites. Elife 6:e21856. https://doi.org/10.7554/eLife.21856

201. Skoutri-Stathaki K, Proudfoot NJ (2014) A double-edged sword: R loops as threats to genome integrity and powerful regulators of gene expression. Genes Dev 28:1384–1396. https://doi.org/10.1101/gad.242990.114

202. Sommakia S, Houlihan PR, Deane SS, Simcox JA, Torres NS, Patel MS, Beal MF (2004) Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. J Mol Cell Cardiol 36:1123–1133. https://doi.org/10.1016/j.yjmcc.2010.10.034

203. Steinhagen T, Voigt T, Fuchs J, Pfau P, Mestdagh P, IzumiKawa K, Mestdagh D, Beal MF (2016) Mitochondrial acute-lipoxygenase 5-methylcytosine and 6-methylamino-purine in bacterial DNA. Nature 38:796–807. https://doi.org/10.1089/dna.2019.4731

204. Tajima H, Niikura T, Hashimoto Y, Ito Y, Kita Y, Terashita K, Yamazaki K, Koto A, Aiso S, Nishimoto I (2002) Evidence for in vivo production of Humanin peptide, a neuroprotective factor against Alzheimer’s disease-related insults. Neurosci Lett 324:227–231. https://doi.org/10.1016/s0304-3900(02)00199-4

205. Thummasorn S, Shinlapawittayatorn K, Chaimanee P, Chaimanee P, Chaimanee P, Chaimanee P, Chaimanee P (2017) High-dose Humanin analogue applied during ischemia exerts cardioprotection against ischemia/reperfusion injury by reducing mitochondrial dysfunction. Cardiovasc Ther 35:12289. https://doi.org/10.1111/1755-5922.12289

206. Tajima H, Niikura T, Hashimoto Y, Ito Y, Kita Y, Terashita K, Yamazaki K, Koto A, Aiso S, Nishimoto I (2002) Evidence for in vivo production of Humanin peptide, a neuroprotective factor against Alzheimer’s disease-related insults. Neurosci Lett 324:227–231. https://doi.org/10.1016/s0304-3900(02)00199-4

207. Tajima H, Niikura T, Hashimoto Y, Ito Y, Kita Y, Terashita K, Yamazaki K, Koto A, Aiso S, Nishimoto I (2002) Evidence for in vivo production of Humanin peptide, a neuroprotective factor against Alzheimer’s disease-related insults. Neurosci Lett 324:227–231. https://doi.org/10.1016/s0304-3900(02)00199-4

208. Tajima H, Niikura T, Hashimoto Y, Ito Y, Kita Y, Terashita K, Yamazaki K, Koto A, Aiso S, Nishimoto I (2002) Evidence for in vivo production of Humanin peptide, a neuroprotective factor against Alzheimer’s disease-related insults. Neurosci Lett 324:227–231. https://doi.org/10.1016/s0304-3900(02)00199-4

209. Tajima H, Niikura T, Hashimoto Y, Ito Y, Kita Y, Terashita K, Yamazaki K, Koto A, Aiso S, Nishimoto I (2002) Evidence for in vivo production of Humanin peptide, a neuroprotective factor against Alzheimer’s disease-related insults. Neurosci Lett 324:227–231. https://doi.org/10.1016/s0304-3900(02)00199-4

210. Tajima H, Niikura T, Hashimoto Y, Ito Y, Kita Y, Terashita K, Yamazaki K, Koto A, Aiso S, Nishimoto I (2002) Evidence for in vivo production of Humanin peptide, a neuroprotective factor against Alzheimer’s disease-related insults. Neurosci Lett 324:227–231. https://doi.org/10.1016/s0304-3900(02)00199-4

211. Tajima H, Niikura T, Hashimoto Y, Ito Y, Kita Y, Terashita K, Yamazaki K, Koto A, Aiso S, Nishimoto I (2002) Evidence for in vivo production of Humanin peptide, a neuroprotective factor against Alzheimer’s disease-related insults. Neurosci Lett 324:227–231. https://doi.org/10.1016/s0304-3900(02)00199-4
and their implications in translational research. Epigenomics 8:551–562. https://doi.org/10.2217/epi.16.3

220. Villegas J, Burzio V, Villota C, Landerer E, Martinez R, Santander M, Martinez R, Pinto R, Vera MI, Boccardo E, Villa LL, Burzio LO (2007) Expression of a novel non-coding mitochondrial RNA in human proliferating cells. Nucleic Acids Res 35:7336–7347. https://doi.org/10.1093/nar/gkm863

221. Wai T, Garcia-Prieto J, Baker MJ, Merkwirth C, Benit P, Rustin P, Ruperez FJ, Barbas C, Ibanez B, Langer T (2015) Imbalanced OPA1 processing and mitochondrial fragmentation cause heart failure in mice. Science 350:aad0116. https://doi.org/10.1126/science.aad0116

222. Wallace DC (2015) Mitochondrial DNA variation in human radiation and disease. Cell 163:33–38. https://doi.org/10.1016/j.cell.2015.08.067

223. Walsh RJ, Mangurian LP, Posner BI (1990) Prolactin receptors in the primate choroid plexus. J Anat 168:137–141

224. Wang J, Jia Z, Zhang C, Sun M, Wang W, Chen P, Ma K, Zhang Y, Li X, Zhou C (2014) miR-499 protects cardiomyocytes from H 2O 2-induced apoptosis via its effects on Pdcd4 and Pacs2. RNA Biol 11:339–350. https://doi.org/10.4161/rna.28300

225. Wang K, Gan TY, Li N, Liu CY, Zhou LY, Gao JN, Chen C, Wang X, Song C, Zhou X, Han X, Li J, Wang Z, Shang H, Liu YE, Hnisz D, Jaenisch R, Bradner JE, Gray NS, Young RA (2017) YY1 is a structural regulator of enhancer-promoter loops. Cell 171(1573–1588):e1528. https://doi.org/10.1016/j.cell.2017.11.008

226. Wang Z, Guo W, Kuang X, Hou S, Liu H (2017) Nanopreparation and disease. Cell 163:33–38. https://doi.org/10.1016/j.cell.2017.04.017

227. Wang X, Song C, Zhou X, Han X, Li J, Wang Z, Shang H, Liu Y, Cao H (2017) Mitochondria associated microRNA expression profiling of heart failure. Biomed Res Int 2017:4042509. https://doi.org/10.1155/2017/4042509

228. Wang K, Gao TY, Li N, Liu CY, Zhou LY, Gao JN, Chen C, Yan KW, Ponnusamy M, Zhang YH, Li PF (2017) Circular RNA mediates cardiomyocyte death via miRNA-dependent upregulation of MTP18 expression. Cell Death Differ 24:1111–1120. https://doi.org/10.1038/cdd.2017.61

229. Wang X, Song C, Zhou X, Han X, Li J, Wang Z, Shang H, Liu Y, Cao H (2017) Mitochondria associated microRNA expression profiling of heart failure. Biomed Res Int 2017:4042509. https://doi.org/10.1155/2017/4042509

230. Wang Z, Guo W, Kuang X, Hou S, Liu H (2017) Nanopreparation for mitochondria targeting drug delivery system: current strategies and future prospective. Asian J Pharm Sci 12:498–508. https://doi.org/10.1016/j.ajps.2017.05.006

231. Weintraub AS, Li CH, Zamudio AV, Sigova AA, Hannett NM, Bruning JC, Kahn CR, Clayton DA, Barsh GS, Thoren P, Larsen MM, van der Made I, van den Oever S, Hiller M, de Niederhausern WJ, Creemers EE (2014) Cardiomyocyte-specific miRNA-30c ablation causes dilated cardiomyopathy. PLoS ONE 9:e96290. https://doi.org/10.1371/journal.pone.0096290

232. Williams RS (1995) Cardiac involvement in mitochondrial diseases, and vice versa. Circulation 91:1266–1268. https://doi.org/10.1161/01.cir.91.4.1266

233. Wilusz JE (2018) A 360 degrees view of circular RNAs: from biogenesis to functions. Wiley Interdiscip Rev RNA 9:e1478. https://doi.org/10.1002/wrna.1478

234. Wright RH, Lioutas A, Le Dily F, Soronellas D, Pohl A, Bonet J, Nacht AS, Samino S, Font-Mateu J, Vicent GP, Wierer M, Trabado MA, Schellhorn C, Carolis C, Macias MJ, Yanes O, Oliva B, Beato M (2016) ADP-ribose-derived nuclear ATP synthesis by NUDIX5 is required for chromatin remodeling. Science 352:1221–1225. https://doi.org/10.1126/science.aad9335

235. Wu Z, Sun H, Wang C, Liu W, Liu M, Zhu Y, Xu W, Jin H, Li J (2020) Mitochondrial genome-derived circRNA mc-COX2 functions as an oncogene in chronic lymphocytic leukemia. Mol Ther Nucleic Acids 20:801–811. https://doi.org/10.1016/j.omtn.2020.04.017

236. Xiao CL, Zhu S, He M, Chen ZQ, Chen Y, Yu G, Liu J, Xie SQ, Luo F, Liang Z, Wang DP, Bo XC, Xu XF, Wang K, Yan GR (2018) (N6)-methyladenine DNA modification in the human genome. Mol Cell 71(306–318):e307. https://doi.org/10.1016/j.molcel.2018.06.015

237. Xiaoy, Zhang X, Fan S, Cui G, Shen Z (2016) MicroRNA-497 inhibits cardiac hypertrophy by targeting Sirt4. PLoS ONE 11:e0168078. https://doi.org/10.1371/journal.pone.0168078

238. Xie Q, Wu KP, Gimple CR, Li Z, Prager BC, Wu Q, Yu Y, Wang P, Yang Y, Gorkin DU, Zhang C, Diwiaik AV, Lin K, Zeng C, Sui Y, Kim LJY, Miller TE, Jiang L, Lee CH, Huang Z, Fang X, Zhai K, Mack SC, Sander M, Bao S, Kerstetter-Fogle AE, Sloan AE, Xiao AZ, Rich JN (2018) N(6)-methyladenine DNA modification in Glioblastoma. Cell 175(1228–1243):e1220. https://doi.org/10.1016/j.cell.2018.10.006

239. Xu HX, Cui SM, Zhang YM, Ren J (2020) Mitochondrial Ca(2+) regulation in the etiology of heart failure: physiological and pathophysiological implications. Acta Pharmacol Sin 41:1301–1309. https://doi.org/10.1038/s41401-020-0476-5

240. Yan K, An T, Zhao M, Huang Y, Wang Q, Wang Y, Zhang R, Wang T, Liu J, Zhang Y, Zhang J, Wang K (2019) Mitochondrial miR-762 regulates apoptosis and myocardial infarction by impairing ND2. Cell Death Dis 10:500. https://doi.org/10.1038/s41419-019-1734-7

241. Yang KC, Yamada KA, Patel AY, Topkara VK, George I, Cheema FH, Ewald GA, Mann DL, Nerbonne JM (2014) Deep RNA sequencing reveals dynamic regulation of myocardial noncoding RNAs in failing human heart and remodeling with mechanical circulatory support. Circulation 129:1009–1021. https://doi.org/10.1161/CIRCULATIONAHA.113.003863

242. Yasukawa T, Kang D (2018) An overview of mammalian mitochondrial DNA replication mechanisms. J Biochem 164:183–193. https://doi.org/10.1093/jb/mvy058

243. Yasukawa T, Reyes A, Cluet TJ, Yang MY, Bowmaker M, Jacobs HT, Holt JJ (2006) Replication of vertebrate mitochondrial DNA entails transient ribonucleotide incorporation throughout the lagging strand. EMBO J 25:5358–5371. https://doi.org/10.1038/sj.emboj.7601392

244. Young MJ, Copeland WC (2016) Human mitochondrial DNA replication machinery and disease. Curr Opin Genet Dev 38:52–62. https://doi.org/10.1016/j.gde.2016.03.005

245. Yu Y, Liu Y, An W, Song J, Zhang Y, Zhao X (2019) STING-mediated inflammation in Kupffer cells contributes to progression of nonalcoholic steatohepatitis. J Clin Invest 129:546–555. https://doi.org/10.1172/JCI121842

246. Zaglia T, Ceriotti P, Canipo A, Borile G, Armani A, Carullo P, Prando V, Coppini R, Vida V, Stolen TO, Ulrik W, Cerbai E, Stellin G, Faggian G, De Stefani D, Sandri M, Rizzuto R, DiLisa F, Pozzan T, Catalucci D, Mongillo M (2017) Content of mitochondrial calcium unipporter (MCU) in cardiomyocytes is regulated by microRNA-1 in physiologic and pathologic hypertrophy. Proc Natl Acad Sci U S A 114:E9006–E9015. https://doi.org/10.1073/pnas.1708772114
248. Zhang D, Li Y, Heims-Waldron D, Bezzeredes V, Guatimosim S, Guo Y, Gu F, Zhou P, Lin Z, Ma Q, Liu J, Wang DZ, Pu WT (2018) Mitochondrial cardiomyopathy caused by elevated reactive oxygen species and impaired cardiomyocyte proliferation. Circ Res 122:74–87. https://doi.org/10.1161/CIRCRESAHA.117.311349

249. Zhang G, Huang H, Liu D, Cheng Y, Liu X, Zhang W, Yin R, Zhang D, Zhang P, Liu J, Li C, Liu B, Luo Y, Zhu Y, Zhang N, He S, He C, Wang H, Chen D (2015) N6-methyladenine DNA modification in Drosophila. Cell 161:893–906. https://doi.org/10.1016/j.cell.2015.04.018

250. Zhang X, Ji R, Liao X, Castillero E, Kennel PJ, Brunjes DL, Franz M, Mobius-Winkler S, Drosatos K, George I, Chen EI, Colombo PC, Schulze PC (2018) MicroRNA-195 regulates metabolism in failing myocardium via alterations in Sirtuin 3 expression and mitochondrial protein acetylation. Circulation 137:2052–2067. https://doi.org/10.1161/CIRCUlationAHA.117.030486

251. Zhang X, Zuo X, Yang B, Li Z, Xue Y, Zhou Y, Huang J, Zhao X, Zhou J, Yan Y, Zhang H, Guo P, Sun H, Guo L, Zhang Y, Fu XD (2014) MicroRNA directly enhances mitochondrial translation during muscle differentiation. Cell 158:607–619. https://doi.org/10.1016/j.cell.2014.05.047

252. Zhao Q, Liu J, Deng H, Ma R, Liao JY, Liang H, Hu J, Li J, Guo Z, Cai J, Xu X, Gao Z, Su S (2020) Targeting mitochondria-located circRNA SCAR Alleviates NASH via reducing mROS output. Cell 183(76–93):e22. https://doi.org/10.1016/j.cell.2020.08.009

253. Zhao Y, Ponnusamy M, Liu C, Tian J, Dong Y, Gao J, Wang C, Zhang Y, Zhang L, Wang K, Li P (2017) MiR-485-5p modulates mitochondrial fission through targeting mitochondrial anchored protein ligase in cardiac hypertrophy. Biochim Biophys Acta Mol Basis Dis 1863:2871–2881. https://doi.org/10.1016/j.bbadis.2017.07.034

254. Zheng H, Xie W (2019) The role of 3D genome organization in development and cell differentiation. Nat Rev Mol Cell Biol 20:535–550. https://doi.org/10.1038/s41580-019-0132-4